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1. Introduction
Anti-cancer sesquiterpene lactones have been isolated from 
several medicinal plants; for example, parthenolide (PTL) (Fig. 
1) [1] isolated from feverfew (Tanacetum parthenium) and
melampomagnolide B (MMB) (Fig. 1) from Magnolia
grandiflora [2], have been the source of several potent anti-
cancer sesquiterpene lactone derivatives that are effective against
both hematological and solid tumors [3-6]. Sesquiterpene
lactones PTL and MMB have both been shown to inhibit the
activation of the nuclear factor kappa B (NF-κB; p65/p50)
transcription factor complex, causing a down-regulation of anti-
apoptotic genes under NF-κB control (Fig. 2) [7, 8]. Utilizing 
streptavidin pull-down and LC/MS/MS peptide sequencing
methodologies with a novel MMB-biotin conjugate,[9] we have
demonstrated that both the inhibitor-of-kappa kinase beta subunit
(IKKβ) and transcription factor p65 (relA) proteins of the NF-κB
pathway can be identified as potential targets in the mechanism
of action of MMB and PTL.
*Corresponding author. Tel.: +1 501 686 6495; fax: +1 501 686 6057. E-mail 
address: pacrooks@uams.edu (P.A. Crooks).
Figure 1: The anti-cancer sesquiterpene lactones parthenolide (PTL), 
DMAPT, melampomagnolide B (MMB), and MMB carbonate and carbamate 
dimers 1 and 2, respectively. 
These sesquiterpene lactones are believed to inhibit IKKβ 
mediated phosphorylation of the inhibitor-of-kappaB 
(IκB)/p65p50 complex [10]. The IκB/p65p50 complex represents 
an inactivated cytoplasmic form of NF-κB, which prevents 
nuclear translocation of NF-κB. In cancer cells, cell membrane-
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Triazole derivatives of melampomagnolide B (MMB) have been synthesized via click chemistry 
methodologies and screened against a panel of 60 human cancer cell lines.  Several derivatives showed 
promising anti-cancer activity, affording growth inhibition (GI50) values in the nanomolar range (GI50
= 0.02-0.99 µM). Lead compound 7h exhibited EC50 values of 400 nM and 700 nM, respectively, 
against two AML clinical specimens. Compound 7h was significantly more potent than parthenolide 
as an inhibitor of p65 phosphorylation in both hematological and solid tumor cell lines, indicating its 
ability to inhibit the NF-κB pathway. In TMD-231 breast cancer cells, treatment with 7h reduced DNA 
binding activity of NF-κB through inhibition of IKK-β mediated p65 phosphorylation and caused 
elevation of basal IκBα levels through inhibition of constitutive IκBα turnover and NF-κB activation. 
Molecular docking and dynamic modeling studies indicated that 7h interacts with the kinase domain 
of the monomeric IKKβ subunit, leading to inhibition of IKKβ activation, and compromising 
phosphorylation of downstream targets of the NF-κB pathway; dynamic modeling studies show that 
this interaction also causes unwinding of the α-helix of the NEMO binding site on IKKβ. Molecular 
docking studies with 10, a water-soluble analogue of 7h, demonstrate that this analog interacts with 
the dimerization/oligomerization domain of monomeric IKKβ and may inhibit oligomer formation and 
subsequent autophosphorylation. Sesquiterpene lactones 7h and 10 are considered ideal candidates for 
potential clinical development. 
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phosphorylates the IκB/p65p50 complex, releasing 
phosphorylated IκB (which is programed for subsequent 
ubiquitinylation and proteasomal degradation), and 
phosphorylated p65p50 (NF-κB), which can then interact with its 
DNA binding site to up-regulate anti-apoptotic gene transcription 
(Fig. 2). During this process, disassociation of IκB releases the 
NF-κB heterodimer inducing its location to the nucleus, where it 
binds to specific gene promoters that inhibit apoptosis.  
 
The anti-cancer activity of PTL is not solely due to NF-κB 
inhibition [7, 11, 12], but rather arises from a broad set of 
biological responses, which likely include inhibition of 
components of glutathione biosynthesis and catabolism [13], 
leading to an increase in reactive oxygen species (ROS) [14]. We 
have previously shown that PTL perturbs glutathione 
homeostasis in primary AML stem cells via a multifactorial 
mechanism, causing an increase in ROS and resulting in 
promotion of apoptosis (Fig. 2) [14].  Utilization of the MMB-
biotin probe in streptavidin pull-down and peptide sequencing 
studies and homology molecular modeling studies both indicate 
that the sesquiterpene lactones PTL and MMB target the 
modulatory (GCLM) and catalytic (GCLC) units of the 
glutathione-cysteine ligase enzyme (which is the rate-limiting 
step in glutathione biosynthesis) and the enzymes glutathione 
peroxidase (GPX1) and thioredoxin (TRX) [14].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Proposed mechanism of action of the sesquiterpene lactones 
parthenolide (PTL), DMAPT and melampomagnolide B (MMB):  A primary 
mechanism involves inhibition of IKKβ activation, causing decreased 
phosphorylation of IκB and/or p65, resulting in down-regulation of anti-
apoptotic gene transcription and sensitization of cancer cells to apoptotic 
signals. A secondary synergistic mechanism involves inhibition of the 
mitochondrial glutathione system, causing an increase in reactive oxygen 
species (ROS) and oxidative stress leading to mitochondrial dysfunction and 
activation of intrinsic apoptosis in cancer cells. 
It has previously been demonstrated that PTL induces robust 
apoptosis of primary acute myeloid leukemia (AML) stem 
cells.[15, 16] However, PTL suffers from poor water-solubility 
and low bioavailability. To improve the water-solubility and 
drug-likeness of PTL we synthesized a dimethylamino analog of 
parthenolide, DMAPT (Fig. 1), by reaction of PTL with 
dimethylamine under Michael addition reaction conditions. The 
water-soluble fumarate salt of DMAPT exhibited similar anti-
leukemic activity as PTL[17] and is currently in Phase I clinical 
studies for evaluation as a treatment for AML and other related 
leukemias[16]. Several other Michael adducts of PTL have been 
synthesized and evaluated for their anti-leukemic activity.[17-19]   
The sesquiterpene lactone MMB has been the source of several 
synthetic anti-leukemic molecules arising from our program over 
the past few years [3-6, 21]. In this respect, MMB can be 
conveniently synthesized from PTL utilizing a modification of 
the method of Macias et al [20] via a one-step selenium oxide 
oxidation of the C10 methyl group of PTL to a hydroxymethyl 
moiety. This reaction occurs with concomitant conversion of the 
geometry of the C9–C10 bond from trans to cis [9]. Like PTL, 
MMB exhibits anti-leukemic properties [9]; however, unlike 
PTL, the structure of the MMB molecule provides more scope 
and greater opportunities for generating new chemical space 
around this interesting sesquiterpene lactone scaffold, since the 
molecule possesses an allylic hydroxyl group at C-14, which 
allows the synthesis of new MMB derivatives via conjugation 
and functional group transformations at this site. Thus, we have 
used a C-14 biotin-conjugated derivative of MMB for elucidating 
the mechanism of action of MMB in AML stem cells [9] and we 
have synthesized a variety of conjugated derivatives of MMB 
which exhibit potent anti-cancer activity against a wide variety of 
human cancer cell lines [3-6, 21]. We have also reported on some 
novel carbamate, and carbonate dimers of MMB (e.g. 1 & 2, Fig. 
1), which represent some of the most potent anti-cancer 
sesquiterpene lactone analogs currently known [4]. 
Based on these important findings, and to further probe the 
chemical space around the MMB molecule, in this current study 
we describe the synthesis of several MMB-1,2,3-triazole 
derivatives by reaction of a C-14 azido derivative of MMB with a 
variety of substituted aromatic, heterocyclic and aliphatic 
acetylenic reagents via click chemistry methodologies. Click 
chemistry is an important approach for the synthesis of drug-like 
1,2,3-triazole compounds and has become one of the most rapid 
and popular approaches for the synthesis of compound libraries 
[22, 23]. Employing click chemistry methodologies can 
accelerate the drug discovery process, since these relatively facile 
synthetic procedures are usually insensitive to oxygen and water 
[24], utilize readily available reagents, and incorporate simple 
isolation methodologies [25, 26]. 
1,2,3-triazole moieties have been found to be useful heterocyclic 
structural motifs in medicinal chemistry because of their ease of 
synthesis. Compounds containing these moieties have been used 
for a wide variety of pharmacological activities, including 
antibacterial[27, 28], antifungal  [29, 30], antiviral  [31, 32]), 
anti-inflammatory [33, 34] and anticancer [35-39] therapy. The 
triazole moiety contains three nitrogen atoms in a five membered 
heteroaromatic ring, and its incorporation into a potential drug 
molecule can play an important role in enhancing anticancer 
activity through improved water solubility, chemical and 
metabolic stability, and improved pharmacokinetic properties[36, 
40]. Because of their high dipole moment [41] and aromaticity 
1,2,3-triazoles can actively participate in hydrogen bonding, and 
dipole-dipole and π-stacking interactions, which may improve 
binding with target proteins [42-44]. They are also considered as 
amide and peptide bond isosteres [45, 46]. A comprehensive 
review of the medicinal attributes of 1,2,3-triazoles has recently 
been published[47]. In this current communication, copper I 
catalysts have been utilized for the synthesis of a variety of 1,2,3-
triazole analogs of MMB from appropriate azido and acetylenic 
precursors. These molecules have been evaluated as anti-cancer 
agents and their mechanism of action has been investigated. 
 
2. RESULTS AND DISCUSSION 
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MMB (3) was synthesized from PTL via SeO2/tBuOOH 
oxidation [20]. The MMB mesylate 4 was synthesized by initial 
reaction of MMB with methane sulfonyl chloride in 
dichloromethane at 0 oC for 30 min; compound 4 was then 
reacted with sodium azide in the presence of dimethylformamide 
and acetonitrile at 80 oC for 1 h to afford the azido synthon 5. 
Intermediate 5 was then treated with a variety of aromatic, 
aliphatic and heteroaromatic acetylenic reagents (6) in the 
presence of CuI/triethylamine/acetonitrile and water (9:1) at 
ambient temperature to afford the corresponding MMB triazole 
derivatives 7a-7s (Scheme 1). Dimeric triazole derivatives of 
MMB were also synthesized by reaction of an appropriate di-
acetylenic intermediate (8) with azido synthon 5 (Scheme 2).  
A more water-soluble dimethylamino adduct of compound 7h 
was also synthesized; 7h was reacted with dimethylamine in 
methanol under Michael addition conditions to afford the 
corresponding Michael adduct, which was then converted into 
the fumarate salt 10 with fumaric acid in ethanol (Scheme 3). 
The water solubility of 10 was predicted to be 1,000 times greater 
than for 7h (ACD/Percepta 14.1.0), i.e. 0.11 mg/mL versus 
0.00005 mg/mL, respectively. All synthesized compounds were 
purified by column chromatography (silica gel; 
methanol/dichloromethane) to afford analytically pure products 
(Tables 1 & 2) in 57-91% yield. Products were fully 
characterized by 1H NMR, 13C NMR and HRMS spectral 
analysis. 
 
 
 
 
 
 
 
Scheme 1: Synthesis of triazole derivatives of MMB 
 
Table 1. Structures, reaction times, yields, and melting points for triazole 
derivatives of MMB prepared from intermediate 5 
Product Yield 
(%)a 
Time (hr) Mp (oC) 
 
7a 
91 6 107-108 
 
7b 
85 10 75-76 
 
7c 
87 6 74-75 
 
7d 
85 8 98-99 
 
7e 
86 8 108-109 
 
7f 
80 8 97-98 
 
7g 
85 8 80-81 
 
7h 
89 4 106-107 
 
7i 
80 6 130-132 
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7j 
86 5 105-106 
 
7k 
75 6 110-112 
 
7l 
79 8 115-117 
 
7m 
75 12 181-182 
 
7n 
80 12 132-133 
7o 
81 10 143-144 
 
7p 
83 16 95-97 
 
75 12 65-66 
7q 
 
7r 
77 12 64-65 
 
7s 
70 10 72-73 
 
 
 
 
 
 
 
Scheme 2. Synthesis of triazole dimers of MMB 
 
Table 2. Structures, reaction times, yields, and melting points for dimeric 
triazole analogs of MMB prepared from intermediate 5. 
Product Yield 
(%)a 
Time 
(hr) 
Mp (oC) 
 
 
9a 
 
 
 
57 
 
 
 
15 
 
 
 
195-197 
 
9b 
80 16 150-151 
 
9c 
70 16 142-143 
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Scheme 3. Synthesis of compound 10, the dimethylamino Michael adduct of      
7h  
2.2. BIOLOGICAL ACTIVITY 
2.2.1. In vitro growth inhibition data against a panel of 60 
human cancer cell lines 
The above triazole derivatives of MMB were evaluated for 
growth inhibitory properties against an NCI panel of 60 human 
cancer cell lines derived from nine cancer cell types, grouped into 
disease sub-panels that represent leukemia, lung, colon, central 
nervous system (CNS), melanoma, renal, ovary, breast, and 
prostate cancer cells. Growth inhibitory (GI50) effects were 
measured as a function of the variation of optical density as a 
percentage of control. The compounds were first screened at a 
single concentration of 10-5 M. Compounds which showed more 
than 60% growth inhibition in at least eight of the sixty cell lines 
in the panel were selected for a complete dose response study 
with five different concentrations (10-4 M, 10-5 M, 10-6 M, 10-7 M 
and 10-8 M) of drug.  
All synthesized compounds were submitted to the NCI screening 
program and compounds 7a, 7c-7f, 7h, 7m-7o and 7q, were 
selected for single dose screening. Based on the single dose 
results, all ten compounds were selected for five-dose testing 
(Table 3). Among these compounds, two analogs: 7h and 7d, 
exhibited potent growth inhibition (GI50 < 1µM) against 66% and 
50%, respectively, of all the cell lines in the 60-cell panel. 
Compounds 7e, 7f and 7m afforded GI50 values of < 1µM in 
40%, 32% and 24% of the cell lines in the panel. Compounds 7h, 
7d, and 7e were effective against the 6-cell lines in the leukemia 
sub-panel, and exhibited GI50 values over the ranges 0.10-0.23 
µM, 0.20-0.50 µM, and 0.24-1.41 µM, respectively. Compounds 
7h, 7d and 7e were also effective anti-cancer agents against the 
subpanel of human colon cancer cell lines with GI50 values over 
the ranges 0.14-1.17 µM, 0.16-1.78 µM and 0.28-1.74 µM, 
respectively. Against the nine cell lines in the melanoma 
subpanel, 7h and 7d afforded GI50 values of 0.15-1.47 µM and 
0.28-1.70 µM, respectively. Compounds 7h, 7d and 7e were also 
potent anti-cancer agents against the eight cell lines in the human 
renal cancer sub-panel, with GI50 values of 0.02-0.70 µM, 0.18-
1.52 µM, and 0.18-1.82 µM, respectively.  7h was particularly 
effective against the RXF 393 renal cancer cell line with a GI50 
value of 0.02 µM and was also a potent anti-cancer agent against 
the ovarian cancer cell subpanel (GI50 0.15-1.86 µM), the 
prostate cancer cell panel (GI50 0.72-0.83 µM), and the breast 
cancer cell subpanel (GI50 0.17-1.03 µM).  
 
Table 3. Growth inhibition (GI50) dataa for compounds 7a, 7c-7f, 7h, 7m-7o and 7q against a panel of 60 human cancer cell lines 
Panel/cell line 7a 7c 7d 7e 7f 7h 7m 7n 7o 7q 
 
GI50a 
(µM) 
GI50a 
(µM) 
GI50a 
(µM) 
GI50a 
(µM) 
GI50a 
(µM) 
GI50a 
(µM) 
GI50a 
(µM) 
GI50a 
(µM) 
GI50a 
(µM) 
GI50a 
(µM) 
Leukemia          
CCRF-CEM 0.99 0.76 0.20 0.24 0.29 0.16 0.45 1.63 2.0 3.00 
HL-60(TB) 1.49 2.58 0.33 0.72 1.17 0.19 0.64 1.91 2.23 3.53 
K-562 1.76 2.40 0.40 0.94 1.30 0.23 1.39 2.51 2.99 3.96 
MOLT-4 1.29 3.03 0.31 0.38 1.13 0.19 2.38 2.59 2.87 5.54 
RPMI-8226 1.71 1.87 0.50 1.41 1.87 0.22 1.18 2.45 2.75 5.52 
SR 1.06 0.81 0.23 0.25 0.25 0.10 1.26 0.56 0.70 2.88 
Non-Small Cell Lung 
Cancer 
          
A549/ATCC 5.88 7.23 1.79 3.37 10.9 1.36 1.73 8.61 11.9 22.3 
EKVX 6.87 2.32 1.57 1.49 2.47 1.50 1.22 2.33 3.89 11.5 
HOP-62 7.41 4.73 1.94 3.04 10.5 1.56 1.77 4.90 10.2 14.1 
HOP-92 1.42 1.48 0.25 0.34 1.13 0.34 0.43 1.66 2.13 2.94 
NCI-H226 4.60 1.73 1.71 2.48 1.99 1.65 1.46 2.09 3.34 12.6 
NCI-H23 5.38 1.75 1.58 1.78 2.06 1.12 1.77 1.82 2.49 13.6 
NCI-H322M 7.79 10.8 2.17 4.39 10.7 1.67 11.1 10.5 12.6 21.5 
NCI-H460 7.74 3.97 2.13 3.66 8.45 1.22 3.16 4.71 10.4 21.2 
NCI-H522 0.81 1.38 0.29 0.25 0.38 0.12 0.28 1.39 1.37 3.06 
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HCC-2998 6.16 1.85 1.64 1.74 1.98 1.17 1.72 1.84 3.49 15.1 
HCT-116 1.17 1.26 0.16 0.29 0.48 0.15 0.33 1.16 1.55 3.98 
HCT-15 0.77 1.05 0.19 0.28 0.33 0.19 0.20 1.11 1.42 2.90 
HT29 1.79 1.79 0.51 0.69 1.23 0.19 0.50 1.66 2.14 5.50 
KM12 8.48 5.88 1.78 1.70 3.51 1.04 2.31 6.45 11.4 17.6 
SW-620 1.50 1.24 0.33 0.42 0.49 0.19 0.42 1.32 2.16 4.23 
CNS Cancer           
SF-268 5.63 2.09 1.59 1.69 2.07 1.08 1.52 2.53 3.70 13.7 
SF-295 7.89 10.3 3.41 5.73 11.0 1.19 6.44 9.61 12.1 18.5 
SF-539 2.01 1.76 0.25 0.27 0.34 0.17 1.16 1.80 2.77 8.87 
SNB-19 7.87 10.8 2.40 3.39 6.92 1.71 3.90 9.49 12.7 18.8 
SNB-75 6.21 2.97 1.16 1.25 1.47 1.26 0.52 3.23 4.98 18.5 
U251 7.96 1.83 1.61 2.02 9.45 1.44 1.53 2.50 4.16 14.1 
Melanoma           
LOX IMVI 0.80 1.11 0.28 0.90 1.16 0.15 0.72 1.28 1.51 3.91 
MALME-3M 1.17 1.70 1.20 1.40 1.67 0.52 1.43 1.61 2.18 4.70 
M14 1.78 2.15 0.79 0.94 1.30 0.35 1.50 1.93 2.97 3.99 
MDA-MB-435 2.37 2.18 0.59 1.00 1.14 0.74 1.41 1.85 3.01 10.4 
SK-MEL-2 5.50 2.45 1.66 1.83 1.95 0.34 1.75 2.27 10.6 16.3 
SK-MEL-28 1.06 1.75 0.35 0.82 0.82 0.46 1.40 1.81 2.71 ND 
SK-MEL-5 7.32 1.72 1.70 1.74 2.10 1.47 1.66 1.83 3.47 15.3 
UACC-257 3.78 ND 1.42 1.47 1.78 1.46 1.29 ND ND ND 
UACC-62 1.87 ND 0.62 1.26 1.35 0.34 1.13 ND ND ND 
Ovarian Cancer           
IGROV1 6.95 1.81 0.73 1.17 1.35 0.84 1.29 1.92 2.96 4.63 
OVCAR-3 1.40 1.04 0.47 0.49 0.56 0.15 1.03 1.06 1.62 3.96 
OVCAR-4 3.22 2.77 1.09 1.29 1.52 0.50 0.70 2.48 4.90 9.46 
OVCAR-5 5.70 2.46 1.21 1.47 1.71 1.10 1.74 2.29 6.43 14.1 
OVCAR-8 2.31 2.23 1.31 1.66 2.59 0.88 0.92 2.96 3.04 13.5 
NCI/ADR-RES 6.17 2.99 2.39 3.05 3.08 1.05 2.51 3.79 14.5 15.2 
SK-OV-3 9.95 17.3 3.67 9.78 16.3 1.86 11.7 17.4 18.3 26.0 
Renal Cancer           
786-0 2.63 1.84 0.50 1.06 1.24 0.16 1.50 1.76 1.98 11.3 
A498 7.80 3.86 1.52 1.82 2.35 0.43 1.04 2.65 10.4 21.5 
ACHN 0.94 1.45 0.18 0.18 0.29 0.16 1.07 1.32 2.65 3.81 
CAKI-1 1.28 1.31 0.86 1.03 1.03 ND 1.08 1.06 1.77 3.91 
RXF 393 1.55 1.07 0.55 0.87 0.70 0.02 0.96 1.07 1.41 4.80 
SN12C 4.50 2.47 1.40 1.64 1.96 0.70 1.49 2.45 3.48 12.1 
TK-10 1.21 1.71 0.99 1.24 1.42 ND 1.46 1.52 2.25 3.86 
UO-31 0.87 1.23 1.08 1.22 1.27 0.38 0.52 1.35 1.87 11.1 
Prostate Cancer           
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DU-145 2.19 1.42 1.00 0.69 1.11 0.72 1.35 1.43 3.65 4.32 
Breast Cancer           
MCF7 1.08 1.33 0.31 0.35 0.42 0.19 0.43 1.68 2.41 3.35 
MDA-MB-231/ATCC 2.00 1.64 1.09 1.22 1.44 0.33 1.11 1.75 3.45 4.22 
HS 578T 9.78 3.57 2.26 3.68 7.42 1.03 1.94 2.82 4.46 23.4 
BT-549 2.65 2.40 0.77 0.83 1.31 0.17 0.75 1.80 3.05 14.2 
T-47D 1.30 1.70 0.83 0.74 1.43 0.33 0.53 2.03 2.23 4.11 
MDA-MB-468 0.95 1.14 0.56 0.42 0.89 0.42 0.53 1.28 1.77 3.65 
ND: Not determined; GI50 values <1 µM are bolded; aGI50: 50% growth inhibition defined as concentration of drug resulting in a 50% reduction in net protein 
increase compared with control cells. 
2.2.2. Anti-leukemic activity of MMB triazole analogs 7a-7s, 
9a-9c, and 10 against M9 ENL1 and primary AML cells 
The above triazole derivatives of MMB were screened for anti-
leukemic activity against M9 ENL1 and primary AML cell 
lines; the latter cell lines (AML#1 and AML#2) were obtained 
with informed consent from AML patients. Evaluations were 
performed after 24 h of drug exposure using flow cytometric 
analysis by labeling with Annexin V and 7-aminoactinomycin 
D (7-AAD) to delineate apoptotic cell populations. For all 
experiments PTL, MMB and DMAPT were included as 
reference controls. Depending on the potency of the 
compound, dose-response curves (0.5-10 µM) were generated 
to determine the concentration resulting in 50% efficacy 
(EC50). 
Most of the compounds exhibited improved anti-leukemic 
activity when compared to PTL, MMB and DMAPT (Table 4 
and Fig. 3). Compounds 7a, 7d-7h, 7j, and 10 all exhibited 
anti-leukemic activity against M9 ENL1 cells with EC50 values 
< 2 µM. The most promising compound was 7h (EC50 = 0.56 
µM), which exhibited 10-fold improvement in potency over 
PTL (EC50 = 5.9 µM). The above analogs were also cytotoxic 
to AML#1 and AML#2 primary leukemia cell lines, affording 
EC50 values in the range 0.4-2.9 µM; again, the most effective 
compound was 7h with EC50 values of 0.4 and 0.7 µM, 
respectively (Table 5, Fig. 4). Compound 7h was 33-fold and 
15-fold more potent than PTL against AML#1 and AML#2 
primary cell lines, respectively. Similarly, 7h was 37-fold and 
16-fold more cytotoxic when compared to DMAPT and 51-
fold and 35-fold more potent than MMB respectively, against 
AML#1 and AML#2 primary cell lines. The water-soluble 
form of 7h, compound 10, also exhibited anti-leukemic 
activity, with EC50 = 1.7, 1.0 and 2.9 µM against M9 ENL1, 
and primary AML#1 and AML#2 cell lines, respectively. The 
data show that, as was observed with the conversion of PTL to 
its equipotent water-soluble analog, DMAPT [17], compound 
7h can also be converted into the water-soluble dimethylamino 
Michael adduct 10 with retention of the anti-leukemic 
properties of the parent compound.   
Table 4. The anti-leukemic activity of triazole derivatives of MMB against 
M9 ENL1 AML cells 
Compound M9ENL1 Viability   (EC50, µM) 95% CI 
7a 1.9 [1.6-2.1] 
7b 11 [10-12] 
7c 3.9 [3.6-4.4] 
7d 1.6 [1.5-1.6] 
7e 1.7 [1.7-1.8] 
7f 1.4 [1.3-1.6} 
7g 1.2 [1.1-1.4] 
7h 0.56 [0.52-0.60] 
7i >> 10 ND 
7j 1.5 [1.54-1.58] 
7k 3.3 [3.0-3.6] 
7l 3.2 [3.0-3.5] 
7m 9.8 [7.0-14] 
7n 2.7 [2.6-2.8] 
7o 2.8 [2.5-3.1] 
7p 38 [32.9-44.7] 
7q 5.5 [4.9-6.2] 
7r 4.3 [4.0-4.7] 
7s 3.8 [3.7-3.9] 
9a >> 10 ND 
9b 4.0 [3.9-4.3] 
9c 2.3 [2.2-2.4] 
10 1.7 [1.3-2.3] 
PTL 5.9 [5.4-6.5] 
DMAPT 6.9 [6.4-7.3] 
MMB 14 [13-15] 
  a EC50 values are given in µM.  Values below 2 µM are bolded.  
Table 5. The anti-leukemic activity of triazole derivatives of MMB against 
primary AML cell lines 
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(EC50, 
µM) 
95% CI AML#2 
viability 
(EC50, 
µM) 
95% CI 
7d 1.0 (0.9-1.1) 1.7 (1.6-1.8) 
7e 1.1 (1.0-1.3) 1.9 (1.2-2.8) 
7f 2.0 (1.6-2.4) 2.5 (2.2-2.8) 
7g 1.3 (1.1-1.4) 1.2 (1.2-1.3) 
7h 0.4 (0.3-06) 0.7 (0.7-0.8) 
7j 2.8 (2.5-3.0) 2.5 (2.2-2.8) 
7l 5.8 (5.5-6.2) >10 ND 
10 2.9 (2.8-3.1) 3.5 (2.7-4.6) 
PTL 7 (5-9) 4.3 (3.8-4.8) 
DMAPT 11 (10-12) 8.2 (7.1-9.5) 
MMB 24 (22-26) >10     ND 
a EC50 values are given in µM.  Values below 2 µM are bolded 
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Figure 4: Comparative anti-leukemic activity of PTL, DMAPT, MMB, and compounds 7d-7h, 7j, 7l and 10, against primary leukemia cells from two AML 
patients. 
In the dimeric series of analogs, compounds 9b and 9c, which 
incorporate 4,4’-(propylene) and 1,3-phenyl linkers, 
respectively, between the two triazole-MMB units in the 
molecule, exhibited anti-leukemic activity against M9 ENL1 
cells comparable in potency to PTL (EC50 = 4.0 and 2.3 µM, 
respectively). The dimeric analog 9a, which incorporates a 2-
azapropylene unit between the two triazole MMB moieties, 
showed very poor anti-leukemic potency (EC50 = 52 µM) 
(Table 4) against M9 ENL1 cells. From the above data, the 
cytotoxicity of the 4-phenyl analog 7a (EC50 = 1.9 µM) is 
comparable to that for analogs 7c-7g, 7k, and 7o (EC50s = 
0.56-3.9 µM), indicating that introduction of a variety of 
aromatic substituents into the 4-phenyl moiety of 7a has little 
to no effect on potency. The exception is the 3-carboxylate 
analog 7i, which had an EC50 value >10 µM. Substitution at 
the 4-position of the phenyl group in 7a for either a 2-pyridyl 
(7l, EC50 = 3.2 µM) or a 3-thiophenyl (7n, EC50 = 2.7 µM) 
moiety also did significantly affect cytotoxicity. Compound 
7h, which incorporates a 3,5-ditrifluoromethylphenyl moiety at 
C4 of the triazole ring, is clearly the most potent compound in 
the series (EC50 = 0.56 µM) against M9 ENL1 cells. A slight 
loss of potency is observed with the 4-(3,5-difluorophenyl) 
analog, 7j (EC50 = 1.5 µM). A significant loss in cytotoxicity is 
seen when the phenyl ring in 7a is separated from the triazole 
ring by a linker moiety; i.e. compound 7b, which has the 
phenyl ring attached to the MMB triazole ring through an ester 
linker, is less potent (EC50 = 11 µM) compared to 7a (EC50 = 
1.9 µM). Also, somewhat lower potency is observed when the 
4-phenyl ring is replaced with aliphatic moieties, e.g. 
compounds 7p-7s.  
To determine its functional properties, the activity of 7h was 
compared to PTL in assays that measure inhibition of NF-κB 
activation. Primary leukemia cells were treated with varying 
concentrations of PTL and 7h for 6 h, followed by lysis and 
analysis by immunoblot. Inhibition of NF-κB activity was 
assessed by measuring phosphorylation of the NF-κB p65 
subunit at Ser-536. As shown in Fig. 5, a significant loss of 
p65 phosphorylation is observed in the presence of 2.5 µM 7h, 
and for PTL at 10 µM, indicating that 7h is a more potent 
inhibitor of p65 phosphorylation compared to PTL in this 
primary leukemia cell line. 
2.2.4. Effect of 7h and 10 on oxidative stress in primary cells 
from AML patients 
The comparative effects of PTL and 7h on glutathione (GSH) 
and oxidized glutathione (GSSG) levels in primary leukemia 
cells (AML#2) (Fig. 6) were determined. Compound 7h was 
less effective than PTL as an inducer of oxidative stress, and 
dose response studies indicated that although compound 7h 
significantly reduced GSH levels at doses of 2.5 and 5 µM, it 
had less effect on GSSG levels at these concentrations.  
Interestingly, compound 10, the water-soluble analog of 7h, 
had little if any effect on either GSH or GSSG levels (Fig. 6), 
indicating that introduction of the dimethylamino group into 
the structure of 7h via Michael addition chemistry eliminates 
the oxidative stress component of the parent compound. 
 
2.2.3. Inhibition of p65 phosphorylation by 7h in primary cell 
cultures from AML patients 
 
 
 
 
 
 
Figure 5: Inhibition of p65 phosphorylation by PTL and 7h in primary 
leukemia cells (AML#1).   
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Figure 6: Effect of PTL (2.5, 5 and 10 µM), 7h (0.625, 1.25, 2.5 and 5 
µM), and 10 (0.625, 1.25, 2.5 and 5 µM) on GSH and GSSG levels in 
primary leukemia cells (AML#2). 
2.2.5. Inhibition of HSR-GBM1 stem-like glioblastoma cells by 
Compound 7h. 
The HSR-GBM1 [48] cell line is representative of 
glioblastoma multiforme (GBM). This cell line was derived 
from the NIH-approved H9 (WA09) human ESC line 
(Invitrogen, Carlsbad, CA, USA) and was cultured as 
neurospheres on ultra-low attachment plates (Sigma, St. Louis, 
MO) in DMEM/F12 media containing 2% StemPro neural 
supplement (both obtained from Gibco, Carlsbad, CA, USA), 
20 ng/mL basic fibroblast growth factor (bFGF), and 20 ng/mL 
epidermal growth factor (EGF); (both obtained from Millipore, 
Billerica, MA). Cells were passed every 3 days to maintain 
their undifferentiated state [49]. The most potent MMB 
triazole analog 7h was screened for anticancer activity against 
the HSR-GBM1 cells and exhibited potent anticancer activity 
in the low micromolar concentration range (EC50 = 1.11 µM) 
(Fig. 7).     
 
 
 
 
 
 
 
 
 
 
Figure 7: Anti-cancer activity if MMB triazole analog 7h against HSR-
GBM1 stem-like gliobastoma cells. (One-Way ANOVA: ****p<0.001; ns 
= not significant). 
 
2.2.6. Compound 7h is a potent inhibitor of NF-κB and cell 
proliferation in breast cancer cells 
The antiproliferative and NF-κB inhibitory effects of 7h on 
breast cancer cell lines was determined. Estrogen receptor-
positive MCF-7 and estrogen receptor-negative cell lines 
MDA-MB-231 and MDA-MB-436 were treated with various 
concentrations of 7h for 4-5 days, and bromodeoxyuridine 
incorporation-ELISA assays were used to measure cell 
proliferation (Fig. 8A). MDA-MB-231 and MDA-MB-436 cell 
lines used in these experiments are the variants of these cell 
lines derived from a mammary fat tumor (i.e. TMD-231 and 
TMD-436). TMD-231 cells showed highest sensitivity to 7h 
with a GI50 value < 0.5 µM, whereas TMD-436 cells were 
relatively resistant, with a GI50 value of >1 µM (Fig. 8A). Our 
results suggest that 7h targets specific signaling pathways in 
these cancer cell lines to inhibit their proliferation.  
Modeling studies suggested that the IKKβ subunit is one of the 
targets of 7h and thus, 7h treatment should reduce DNA 
binding activity of NF-κB, since IKKβ activation is required 
for the release of phosphorylated p65/p50 (NF-κB) from the 
IκBα complex. [10] NF-κB demonstrates constitutive DNA 
binding in TMD-231 cells, likely due to the autocrine action of 
IL-1α, [50] and treatment of cells with 7h for three hours 
reduced NF-κB DNA binding activity (Fig. 8B). The effect of 
7h is specific to NF-κB, since the drug had no effect on DNA 
binding of Oct-1.  Although the concentration of drug required 
to inhibit NF-κB DNA binding activity is higher than required 
to inhibit cell proliferation, duration of drug exposure is 
different (i.e. three hours versus 4-5 days). Cytokine-mediated 
NF-κB activation involves activation of IKKβ, which 
phosphorylates and promotes degradation of IκBα. [10]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8:  Compound 7h inhibits cell proliferation and NF-κB. A) The 
effect of 7h on proliferation of MDA-MB-231, MCF-7, and MDA-MB-
436 breast cancer cell lines. Cells were treated with the indicated 
concentrations of 7h and cell proliferation was measured by 
bromodeoxyuridine ELISA assay 4-5 days after treatment. Results are 
average values from four experiments, each experiment with six technical 
replicates.  B) Compound 7h inhibits NF-κB DNA binding activity in 
TMD-231 cells. Cells were incubated with different concentrations of 7h 
for three hours and EMSA was performed to measure NF-κB and Oct-1 
DNA binding activity. Antibody supershift assay was used to identify NF-
κB subunits in DNA-protein complex (last two lanes). C) Compound 7h 
prevents IκBα degradation. TMD-231 cells were incubated with vehicle or 
2.5 µM 7h for one hour prior to treatment with TNFα (4 ng/mL). Cells 
were harvested at the indicated time after TNFα treatment and subjected to 
Western blotting. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPTWe next examined the effect of 7h pretreatment on TNFα-
mediated degradation of IκBα to confirm the inhibitory effects 
of 7h on IKKβ. As expected, TNFα treatment caused 
degradation of IκBα within 15 minutes, and the protein levels 
rebounded by one hour (Fig. 8C). In cells pretreated for one 
hour with 2.5 µM 7h, basal IκBα levels were elevated 
compared to untreated cells, suggesting the ability of 7h to 
inhibit constitutive IκBα turnover and NF-κB activation. 
Consequently, TNFα-mediated cytoplasmic IκBα degradation 
was lower in 7h pretreated cells compared to control cells. 
These results confirm NF-κB inhibitory activity of 7h, and 
unlike other previously described NF-κB inhibitors derived 
from sesquiterpene lactones, compound 7h is active in the 
nanomolar range. 
2.3. Structure modeling of the IKKβ protein 
The IKK (IκB kinase) complex is an essential component for 
activation of the NF-κB pathway [51-57]. An activated IKKβ 
subunit is one of the core subunits of the IKK complex, with 
IKKα, and IKKγ (NEMO) being the other core subunits. IKKα 
and IKKβ are structurally related kinase domain (KD)-
containing proteins, whereas NEMO is an obligate scaffolding 
protein subunit and has a higher affinity for IKKβ than for 
IKKα. Perturbing the activation of IKKβ has been shown to 
have a direct effect on the subsequent activation of NF-κB and 
binding of NEMO to IKKβ is considered a significant event in 
activation of the NF-κB pathway [57-60]. These studies have 
also shown that inhibiting IKKβ-mediated phosphorylation of 
the IκB/p65p50 complex prevents activation of NF-κB and the 
subsequent upregulation of anti-apoptotic gene transcription. 
IKKβ is an 86 KD protein containing 756 amino acids [30]; it 
contains four functional domains, namely the KD, the 
ubiquitin-like domain (ULD), the scaffold/dimerization 
domain (SDD) and the NEMO binding domain (NBD). 
Previous studies have determined the importance of each 
domain in the activation and function of IKKβ [28-30]. The 
KD is one of most studied and important domains in the 
activation of IKKβ, which involves phosphorylation of the key 
amino acid residues SER 177 & SER 181 present in the 
activation loop [57]. The ULD is unique, in that it is only 
found in the IKKβ subunit, suggesting an important role for 
this domain in the activation of NF-κB.  In this respect, it has 
been shown that ULD deletion mutants of IKKβ show poor 
catalytic activity, and result in loss of NF-κB activity [61].  
Studies have determined that the monomeric IKKβ subunit 
assembles spontaneously and reversibly into dimers and higher 
order oligomers in solution [30], which is facilitated by the 
SDD. Although IKKβ kinase activity does not depend on 
dimerization mediated via the SDD, inhibiting IKKβ 
dimerization causes loss of interaction with NEMO, and loss of 
NEMO interaction can ultimately lead to poor assembly of the  
 
 
 
 
 
 
 
IKK complex and loss of NF-κB activation [62, 63].  
The Results from our previous studies [9,14,15,17], as well as 
those from the current studies, have shown that the natural 
sesquiterpene lactones PTL and MMB and their synthetic 
analogs inhibit the NF-κB pathway by preventing p65 
phosphorylation, and MMB-biotin protein pull-down 
experiments have identified the IKKβ subunit as a target 
protein [9,14]. Thus, we were particularly interested in 
determining the mechanism of interaction of the novel MMB-
triazole analogs with the IKKβ subunit and its relevance to 
drug design strategies targeting inhibition of IKKβ activation.  
The present molecular modeling study is focused on 
identifying the mechanism of action of the MMB-triazole 
analogs as inhibitors of IKKβ by studying their interaction 
with critical domain binding sites on a full length, structural 
model of the monomeric IKKβ subunit.  
Since there is no available crystal structure for the complete 
monomeric form of human IKKβ (available crystal structures 
of IKKβ  [29-30, 33] lack the NBD region), we modeled a 
complete monomeric IKKβ 3D structure (756 amino acids) 
that included the missing amino acids of the NBD, using the 
fold recognition and ab initio approach from I-TASSER  
(http://zhanglab.ccmb.med.umich.edu/I-TASSER) [64] (Fig. 
9A). We superimposed this predicted structure of monomeric 
full length IKKβ with the monomeric unit in the existing 
crystal structure of the IKKβ dimer (lacking the NBD) (PDB 
code: 4KIK) [65], and the atomic coordinates of our predicted 
model, which includes the SDD, KD, and ULD, coincided well 
with the x-ray crystal structure data (data not shown), 
indicating the confidence level of the predicted model.  
Although available crystal structures of IKKβ that contain KD 
binding sites exist in the oligomeric forms [57], the 
significance of other domains in monomeric IKKβ, i.e. the 
SDD, ULD and NBD, were considered to be of value in 
determining the mechanism of inhibition of IKKβ by 7h and 
10. Thus, we used the full length monomeric structure of IKKβ 
to determine if the lead MMB-triazole analogs might have the 
potential to interact with any of the above four domains to 
inhibit subsequent IKKβ oligomerization/activation. 
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Figure 9: (A) Full length structure of IKKβ containing the Kinase Domain (KD), the ubiquitin-like domain (ULD), the Scaffold Dimerization Domain (SDD) 
and predicted NEMO binding domain (NBD).  (B & C) Predicted region of interaction of compounds 7h and 10, (B) compound 10 binding to the SDD of IKKβ, 
(C) compound 7h binding to the KD of IKKβ.  
3. Molecular docking studies 
 
 
    
Figure 10: (A) Sites of interaction of compounds screened against IKKβ; (B and C) Predicted site of interaction of MMB, PTL, DMAPT and the MMB-triazole 
derivatives 7h and 10, with full length IKKβ: compounds 7h, MMB, and PTL are predicted to interact with the KD (activation site) of IKKβ, whereas DMAPT 
and compound 10 are predicted to interact at the interface of the SDD and the KD of IKKβ (C). (D) Binding free energies of each compound were calculated 
from Raccoon/AutoDock-Vina [66].   
 
Based on the in vitro NCI screening data, the most potent 
compounds, 7h and its water-soluble dimethylamino adduct, 
10, together with PTL, DMAPT, and MMB, were selected for 
docking studies with full length monomeric IKKβ, to identify 
the possible site(s) of action and mechanism(s) of these 
molecules. Docking calculations were performed in 
Raccoon/Autodock-Vina [66] (running on a Linux server). The 
top ranked (most energetically favorable) docking pose of each 
molecule and the site of interaction were analyzed in 
Discovery Studio and LigPlot+ [67]. Molecular docking 
predicted that all the above compounds bind to IKKβ. 
Interestingly, 7h and its water-soluble derivative 10 bind to 
different sites on IKKβ (Fig. 9B and 9C). Compound 7h binds 
directly to the activation loop (KD) of IKKβ and is predicted to 
inhibit the activation of IKKβ by blocking the critical 
phosphorylation residue SER181 and events leading to 
inhibition of phosphorylation of other downstream targets, 
such as IκB and p65. Compound 10 on the other hand, binds 
close to the junction between the SDD and the KD.  The SDD 
is a critical domain involved in the dimerization of IKKβ.  
Recent studies support the involvement of a functional dimeric 
form of IKKβ that can exist in a closed and open conformation, 
the latter conformation allowing subsequent oligomerization to 
occur through interaction of IKKβ monomeric units at 
neighboring KD sites. Fig. 10A illustrates that 7h, PTL and 
MMB both bind to the activation loop of the KD; whereas 
compound 10 and DMAPT (a water-soluble analog of PTL) 
both bind close to the junction between the SDD and the KD 
sites.  Thus, addition of a dimethylamino group at C11 of 
either the PTL molecule (to afford DMAPT) or to the 
equivalent site on 7h (to afford compound 10) changes the site 
of interaction of these molecules with IKKβ.  Interestingly, 
although DMAPT does not interact with the KD site on IKKβ, 
it is still able to inhibit downstream phosphorylation of p65 
[17]. Fig. 10 illustrates the interacting amino acids of IKKβ 
with docked compounds 10 and DMAPT at the SDD site (Fig. 
10B) and with docked compounds 7h, PTL, and MMB at the 
KD site (Fig. 10C). Activation of IKKβ is dependent on 
phosphorylation of SER 177 and SER 181 [62, 68]. Analyzing 
the interacting amino acids of IKKβ with the docked 
compounds at the KD site indicates that compounds 7h, PTL 
and MMB interact with critical amino acid residues, including 
SER 177, CYS 179 and SER 181, in a non-covalent fashion.  
Compound 7h had the highest binding free energy (∆Gbind = -
9.7 kCal/mol) followed by compound 10, MMB, PTL and 
DMAPT (Fig. 10D). 
3.1. in silico site directed mutagenesis  
To determine whether SER181 is a critical residue involved in 
7h-IKKβ binding, we performed in silico site-directed 
mutagenesis studies on the modeled IKKβ molecule by 
converting the SER181 amino acid residue to alanine.  
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binding affinity compared to IKKβ wild type docking, 
indicating that the presence of SER (probably unmodified) at 
the 181 position is critical for 7h binding.  Interestingly, when 
we mutated CYS179 (another critical residue in the kinase 
domain) to alanine, this change did not affect 7h binding, 
indicating that only SER181 is a critical residue involved in 7h 
binding to IKKβ.  The above in silico mutations did not affect 
the binding of any of the other molecules mentioned in these 
studies.    
3.2 Covalent docking 
Since 7h possesses an electrophilic exocyclic double bond and 
is predicted to bind to the CYS179 residue at the KD of IKKβ, 
we wanted to determine whether this molecule could form a 
covalent bond with the CYS179 residue through Michael 
adduct formation.  We used the Glide-CovDock (covalent 
docking) module from the Schrodinger small molecule drug 
discovery suite (Version-2018-1, Schrödinger, LLC, New 
York, NY, 2018) to predict covalent docking. Out of 10 poses, 
the lowest energy conformer was chosen based on cDock 
docking affinity calculations (Table S1, Supporting 
Information).  It was predicted that 7h undergoes Michael 
addition at the exocyclic double bond to form a covalent bond 
with the thiol group of the CYS179 residue. Compound 10 is 
also predicted to interact with a CYS residue (CYS114) at the 
interface of the KD and SDD binding sites, but this interaction 
is not predicted to form a covalent Michael adduct with this 
amino acid residue.  Modeling results also predict that 
DMAPT may be susceptible to a nucleophilic substitution 
reaction, either through an interaction at the epoxide ring or at 
the exocyclic methylene moiety; it is worth noting that the 
cdock affinity value for DMAPT is lower than that for PTL.  
Compound 10, on the other hand, shows very low cdock 
affinity (-1.994), indicating that its ability to undergo covalent 
docking is low. Comparing the cdock scores with other 
molecules, clearly indicates that compound 10 is unlikely to 
undergo covalent docking with CYS114.    Comparing the 
Autodock (binding score) and cdock scores, it is evident that 
compound 10 binds to the SDD-KD site very efficiently 
(Gbind = -8.8 kcal/mol), without forming a covalent bond at 
the site of binding (cdock score = -1.994).  These data our 
interesting, especially in light of our experimental data 
indicating that compound 10 does not appear to inhibit the 
glutathione pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3. Molecular Dynamics simulation of IKKβ-7h & IKKβ-10 
complexes 
To analyze the stability of the interaction of 7h with IKKβ, we 
performed 50ns fully solvated molecular dynamics simulation 
of IKKβ complexed with 7h (Videos 1 and 2a, Supplementary 
Data).  We also ran an undocked IKKβ molecule alone as a 
control (Video 2b, Supplementary Data).  Results (Fig. 11, 
Panels A and B) indicate stable binding of 7h to the kinase 
domain of IKKβ and its interaction with amino acid residues 
SER181 and CYS99 in the simulation. SER181 is one of the 
key amino acid residues involved in the activation of IKKβ 
[57]. 
We also studied ligand-induced structural changes to IKKβ 
during the 50ns simulation with 7h. Interestingly, 7h induces 
notable structural changes to IKKβ (Fig. 11B, and Video 2a, 
Supplementary Data). The beta-sheet region near LYS171 
unwinds in the presence of 7h (panel B), indicating that 
structural changes at the kinase domain of IKKβ occur upon 7h 
binding.  Since 7h binding is juxtaposed close to SER181, one 
of the key residues involved in IKKβ activation (via 
phosphorylation of SER181) [57], this MMB analog could be 
sterically hindering this critical process.  Surprisingly, binding 
of 7h to the KD of IKKβ also induces notable structural 
changes at the NBD (Fig. 11C); i.e., the majority of the NBD 
α-helix conformation (red) unwinds when 7h is bound to the 
KD (Video 3, Supplementary Information).  Since IKKβ binds 
directly to NEMO via the NBD to form the NF-κB 
multiprotein complex, and any intervention that leads to failure 
of NEMO-IKKβ binding leads to inhibition of NF-κB [69], the 
impact of these 7h-induced structural changes are notable and 
may explain the high potency of this compound in inhibiting 
the NF-κB pathway. Compound 10 also exhibited stable 
binding with IKKβ at the junction between the SDD and KD.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: (A & B) Detailed structure of IKKβ alone (A) or complexed with 7h (B) after 50ns simulation. Structures where viewed in Discovery Studio 
visualizer. (C) Secondary structure assignment over 50ns simulation with IKKβ alone (top panel) or when complexed with 7h (bottom panel), where red 
indicates beta-sheet, white indicates loops and turns, and blue indicates alpha-helix. Desmond trajectories were analyzed using the simulation interaction 
diagram module from Maestro (Schrodinger, Inc.).   
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Abbreviations: NBD: NEMO binding domain; SDD: scaffold dimerization domain; ULD: ubiquitin-like domain; KD: kinase domain; APD: auto 
phosphorylation domain 
Figure 12: Interaction of compounds 7 and 10 with IKKβ and the subsequent events in the IKKβ oligomerization activation model. Compound 7h interacts with 
IKKβ at both the NEMO binding domain (NBD) and the kinase domain (KD), blocking transient oligomerization of IKKβ and subsequent trans 
autophosphorylation, while inhibition of the scaffold dimerization domain (SDD) by compound 10 results in inhibition of IKKβ dimerization and subsequent 
curtailment of oligomerization. 
Although 10 does not induce any major structural changes at 
this binding site, it does induce moderate structural changes at 
the SDD by disturbing the helices at several regions of interest 
(see Fig. S1 and Video 3, Supplementary Information).  Also, 
10 interacts with amino acid residues that include CYS114 and 
ARG427, at the junction between the KD and SDD [70]. Since 
the SDD domain participates in IKKβ dimerization, it is likely 
that compound 10 could inhibit IKKβ dimerization and 
subsequent oligomerization.  Studies have shown that 
dimerization of IKKβ plays a critical role for both IKKβ 
activation and NEMO binding [69]. 
Thus, our molecular docking studies with full length 
monomeric IKKβ indicate that 7h is predicted to interact with 
the major activation site (i.e. the KD) on the IKKβ-subunit to 
inhibit the phosphorylation of critical amino acid residues 
SER177 and SER 181, leading to inhibition of the activation of 
the IKKβ subunit. Also, through molecular dynamics 
simulation, it is predicted that binding of 7h at the KD site 
induces significant structural changes to the monomeric IKKβ 
subunit, which could compromise activation. Surprisingly, 
compound 10, the water-soluble analog of 7, does not retain 
the oxidative stress component of the parent compound 7h; 
also, unlike 7h, analog 10 is predicted to bind to a different site 
on the IKKβ subunit (i.e. at the junction between the KD and 
SDD sites, rather than at the KD site), and may inhibit IKKβ 
activity by preventing IKKβ dimerization/oligomerization.  
We predicted that DMAPT, the water soluble analog of PTL, 
binds to the same site as 10 on the IKKβ subunit, indicating 
that the N,N-dimethylamino adducts of PTL and 7h are both 
acting via a different mechanism to their parent compounds. In 
this respect, it has been hypothesized that these α-methylamino 
analogs of sesquiterpene lactones might undergo reverse 
Michael addition in vivo through interaction with biological 
nucleophiles to release the parent sesquiterpene, thereby acting 
as prodrugs[30, 71-74]. We have previously shown that 
DMAPT does undergo a reverse Michael reaction in HEPES 
cell culture buffer, but only 3% conversion to PTL was 
observed over 24 hr [17]. This result is consistent with our 
pharmacokinetic studies with DMAPT fumarate in the rat, 
which showed that DMAPT has an oral bioavailability of 79%, 
and is oxidized in the liver to the major N-demethylated 
metabolite, MAPT (methylaminoparthenolide (13-N-
methyl)amino-4α5β-epoxy-4,10-dimethyl-6α-hydroxy-12-oic-
acid-γ-lactone-germacra-1(10)-ene) with only very small 
amounts of PTL detected in the plasma over 8 hrs post 
administration (unpublished data). 
To determine the potential of compound 10 to form 7h via a 
reverse Michael mechanism, we examined the stability of 10 in 
aqueous solution (D2O/DMSOd6; pH~7) by NMR spectroscopy 
over 8 hrs at 37oC and compared it to DMAPT fumarate 
stability under the same conditions. The results indicate that 
both DMAPT and 7h had a slight propensity (2-3%) to 
undergo a reverse Michael reaction. Thus, we conclude from 
these data that, as observed with DMAPT fumarate, the 
anticancer properties of 10 are likely not related to a prodrug 
mechanism of action for this compound.      
Polley et al. [57] have proposed an IKKβ oligomerization and 
activation model in which the open form of monomeric IKKβ 
forms a dimer which can further oligomerize to a dimer of 
IKKβ dimers (tetramer); subsequent oligomerization can then 
occur to form higher order oligomers that can rapidly amplify 
IKKβ kinase activity through autophosphorylation at adjacent 
KD interfaces (Fig. 12). It has been shown that introduction of 
mutations within these oligomerization interfaces can disrupt 
IKKβ activation, indicating that small molecule entities 
designed to bind to these interfaces may function as specific 
inhibitors of IKKβ activation thereby affecting 
phosphorylation of downstream targets [57, 62] 
The proposed sites of action for compounds 7h and 10 and 
their parent compounds is illustrated in Fig. 12. Based on our 
docking studies with monomeric IKKβ, it is predicted that 
compound 7h interacts with the KD and compound 10 
interacts with critical amino acid residues at the SDD to inhibit 
IKKβ oligomerization and activation, whereas inhibition of 
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trans autophosphorylation of IKKβ oligomers. Both 
mechanisms can result in inhibition of IκB(p65/p50) 
phosphorylation, and inhibition of release of NF-κB from the 
IκB(p65/p50) complex, resulting in down-regulation of anti-
apoptotic gene transcription and apoptosis of cancer cells.  
4. CONCLUSIONS      
Triazole derivatives of MMB exhibit improved potency as 
anti-cancer agents when compared to parent compounds PTL, 
DMAPT and MMB. The most promising compounds, 7h, 7d 
and 7e, showed growth inhibition values in the nanomolar 
range (GI50 = 27-990 nm) against many of the human cancer 
cell lines in the NCI 60 human cancer cell panel. The two most 
active compounds, 7h and 7d afforded sub-micromolar GI50 
values against 66% and 50%, respectively, of all the cancer 
cell lines in the panel, and exhibited effective cytotoxicity 
against all six cell lines in the leukemia subpanel (GI50 values 
of 0.10-0.69 µM and 0.20-0.50 µM, respectively). Compound 
7h exhibited promising anti-cancer activity against cell lines in 
the colon cancer, melanoma, renal cancer, and breast cancer 
sub-panels, and was a particularly potent anti-cancer agent 
(GI50 = 20 nm) against the RXF 393 renal cancer cell line. The 
MMB-triazole analogs were also screened for anti-leukemic 
activity against M9 ENL1 and primary AML cell lines. Most 
of the compounds exhibited anti-leukemic activity in the 
nanomolar to low micromolar concentration range. 
Importantly, 7h showed nanomolar activity (EC50 = 400-700 
nm) against both M9 ENL1 and primary AML cell lines. To 
improve the drug-like properties of compound 7h, the water-
soluble C-11 dimethylamino Michael adduct (10) was 
synthesized and tested for anti-leukemic activity. Compound 
10 exhibited similar anti-leukemic activity as 7h against 
primary AML cells. These MMB-triazole analogs appear to be 
superior to PTL, DMAPT and MMB as both anti-leukemic 
agents and as anti-cancer agents against solid tumors.  
In mechanistic studies, 7h was more potent than PTL as an 
inhibitor of p65 phosphorylation in both hematological and 
solid tumor cell lines, indicating improved ability to inhibit the 
NF-κB pathway. In TMD-231 breast cancer cells, 7h reduced 
DNA binding activity of NF-κB through inhibition of IKKβ 
activation and subsequent p65 phosphorylation. Compound 7h 
also elevated basal IκBα levels when compared to untreated 
cells, indicating the ability of this sesquiterpene lactone 
derivative to inhibit constitutive IκBα turnover and subsequent 
NF-κB activation. Thus, TNFα-mediated IκBα degradation 
was lowered in cells pretreated with 7h compared to control 
cells.  Interestingly, 7h was less effective than PTL in inducing 
oxidative stress through inhibition of glutathione levels in 
primary AML cells, whereas 10 did not exhibit any oxidative 
stress component in its mechanism. 
The MMB-triazole 7h and its water-soluble analog 10 
represent new sesquiterpene lactone analogues that target the 
IKKβ subunit to inhibit phosphorylation of downstream 
elements of the NF-κB pathway. They are potent anticancer 
agents and are regarded as potential candidates for clinical 
development. 
5. EXPERIMENTAL  
In the synthesis of triazole derivatives of MMB, all reagents, 
solvents and chemicals were purchased from Sigma-Aldrich 
Co. LLC.  The synthetic reactions were carried out at ambient 
temperature and the products were purified by flash column 
chromatography (silica gel; methanol/dichloromethane) to 
afford pure compounds in 57-91% yield. Melting points were 
recorded on a Kofler hot-stage apparatus and are uncorrected. 
1H and 13C NMR spectra were recorded on a Varian 400 MHz 
spectrometer equipped with a Linux workstation running on 
vNMRj software. All the spectra were phased, baseline was 
corrected where necessary, and solvent signals (CDCl3) were 
used as reference for both 1H and 13C NMR spectra. Chemical 
shifts are given as δ values in parts per million (ppm) and 
coupling constants (J) are given in hertz (Hz). HRMS data 
were obtained on an Agilent 6210 LCTOF instrument 
operating in multimode. Infrared spectra were recorded on a 
Nicolet iS50 FT-IR spectrometer (Thermo Scientific). Thin-
layer chromatographic (TLC) separations were carried out on 
pre-coated silica gel plates (F 254 Merck). The purity of final 
compounds was determined to be ≥95% by high pressure 
liquid chromatographic (HPLC) analysis on a Model 1290A 
Agilent HPLC-Diode Array unit utilizing an Altima-C18 
column (4.6 × 250 mm, 5 µm); a mobile phase of acetonitrile 
containing 30% Milli Q water at a flow rate of 0.8 mL/min was 
used. UV detection was at 210 nm.    
5.1. Synthetic procedure and analytical data for the azido 
derivative of melampomagnolide B (5) 
Triethylamine (0.158 mL, 1.13 mmol) and methane sulfonyl 
chloride (129.3 mg, 1.13 mmol) were added to a solution of 
MMB (300 mg, 1.13 mmol) in dichloromethane (5 mL) at 0 
oC.  The reaction mixture was stirred at 0 oC for 30 min. After 
completion of the reaction, water was added, and the mixture 
was extracted with dichloromethane. The organic layer was 
washed with water (3x10 mL), dried over Na2SO4 and 
concentrated under reduced pressure to afford MMB mesylate 
(4). Sodium azide (136.8 mg, 2.10 mmol) was added to MMB 
mesylate (360 mg, 1.05 mmol) in acetonitrile/DMF (1:1) (10 
mL). The reaction mixture was heated at 80 oC for 1 h. After 
completion of the reaction, the solvent was evaporated under 
reduced pressure and the crude residue was subjected to 
column purification (silica gel, 30-40 % EtOAc in hexane) to 
afford the pure azido analog 5 as a white solid (200 mg, 61%). 
 1H NMR (CDCl3, 400 MHz): δ 6.27 (d, J = 3.6 Hz, 1H), 5.67 
(t, J = 8.0 Hz, 1H), 5.55 (d, J = 3.6 Hz, 1H), 3.87-3.81 (m, 2H), 
3.70 (d, J = 13.2 Hz, 1H), 2.85 (d, J = 9.6 Hz, 1H), 2.76-2.69 
(m, 1H), 2.49-2.16 (m, 6H), 1.74- 1.66 (m, 1H), 1.55 (s, 3H), 
1.12 (t, J = 12 Hz, 1H) ppm. 13C NMR (CDCl3, 100 MHz) δ 
169.3, 138.7, 134.8, 131.3, 120.5, 81.0, 63.4, 60.0, 55.7, 42.8, 
36.7, 25.5, 24.2, 23.9, 18.1 ppm. FT-IR/ATR 2,089.03 (azido 
moiety), 1751.33, 1265.41, 1250.56, 1146.55, 988.99, 944.22, 
814.25 cm-1. HRMS (ESI) m/z calcd for C15H20N3O3 (M + H)+ 
289.1426, found 289.1417. 
5.2. General Synthetic procedure and analytical data for the 
triazole derivatives of MMB (7a-7s, 9a-9c) 
To the azido analogue of MMB (5, 60 mg, 0.20 mmol) in 
acetonitrile and water (9:1) (3 mL), was added the appropriate 
acetylenic reagent (0.248 mmol), copper iodide (3.8 mg, 0.02 
mmol) and trimethylamine (0.20 mmol). The reaction mixture 
was stirred for 4-16 h. After completion of the reaction the 
solvent was evaporated under reduced pressure to afford a 
crude reaction mass. Water was added to this crude reaction 
mass, and the mixture extracted with EtOAc. The organic layer 
was washed with water (2x5 mL), dried over anhydrous 
Na2SO4, filtered, and the solvent was evaporated under vacuum 
to afford the crude reaction product. The crude product was 
purified by column chromatography (silica gel, 2-5% methanol 
in dichloromethane) to afford the appropriate triazole 
derivative of MMB (yield: 57-91 %). 
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ACCEPTED MANUSCRIPT5.2.1 (1aR,7aS,10aS,10bS,E)-1a-Methyl-8-methylene-5-((4-
phenyl-1H-1,2,3-triazol-1-yl)methyl)-2,3,6,7,7a,8,10a,10b-
octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1aH)-
one (7a).  
1H NMR (CDCl3, 400 MHz): δ 7.84 (d, J = 8 Hz, 2H), 7.73 (s, 
1H), 7.43 (t, J = 7.2 Hz, 2H), 7.34 (t, J = 7.2 Hz, 1H), 6.32 (d, 
J = 3.2 Hz, 1H), 5.80 (t, J = 8.8 Hz, 1H), 5.70 (d, J = 3.2 Hz, 
1H), 5.26 (d, J = 14.4 Hz, 1H), 4.78 (d, J = 14.8 Hz, 1H), 3.86 
(t, J = 9.2 Hz, 1H), 2.89-2.79 (m, 2H), 2.72-2.62 (m, 1H), 
2.48-2.17 (m, 4H), 2.01(d, J = 15.6 Hz, 1H), 1.70-1.62 (m, 
1H), 1.54 (s, 3H), 1.16 (t, J = 11.2 Hz, 1H) ppm. 13C NMR 
(CDCl3, 100 MHz) δ 169.2, 148.5, 138.3, 135.3, 132.3, 130.4, 
129.0, 128.5, 125.8, 121.7, 119.1, 80.9, 63.5, 59.9, 55.0, 42.7, 
36.6, 25.3, 24.2, 23.6, 18.0 ppm. HRMS (ESI) m/z calcd for 
C23H26N3O3 (M + H)+ 392.1969, found 392.1976.  
5.2.2. (1-(((1aR,7aS,10aS,10bS,E)-1a-Methyl-8-methylene-9-
oxo-1a,2,3,6,7,7a,8,9,10a,10b-decahydrooxireno[2',3':9,10]cy 
clodeca[1,2-b]furan-5-yl)methyl)-1H-1,2,3-triazol-4-yl)methyl 
benzoate (7b).  
1H NMR (CDCl3, 400 MHz): δ 8.05 (d, J = 7.2 Hz, 2H), 7.66 
(s, 1H), 7.57 (t, J = 7.6 Hz, 1H), 7.44 (t, J = 8 Hz, 2H), 6.31 (d, 
J = 3.60 Hz, 1H), 5.77 (t, J = 8 Hz, 1H), 5.67 (d, J = 3.2 Hz, 
1H), 5.51-5.43 (m, 2H), 5.20 (d, J = 14.4 Hz, 1H), 4.72 (d, J = 
14.4 Hz, 1H), 3.85 (t, J = 9.2 Hz, 1H), 2.86 (d, J = 9.2 Hz, 1H), 
2.80-2.74 (m, 1H), 2.65-2.56 (m, 1H), 2.46-2.17 (m, 4H), 1.97-
1.93 (m, 1H), 1.69-1.61 (m, 1H), 1.53 (s, 3H), 1.14 (t, J = 13.2 
Hz, 1H) ppm. 13C NMR (CDCl3, 100 MHz) δ 169.2, 166.6, 
143.7, 138.2, 134.9, 133.4, 132.7, 129.9, 129.8, 128.5, 123.7, 
121.1, 80.9, 63.5, 59.9, 58.1, 55.0, 42.7, 36.6, 25.3, 24.2, 23.6, 
18.0 ppm. HRMS (ESI) m/z calcd for C25H28N3O5 (M + H)+ 
450.2023, found 450.2001.  
5.2.3. (1aR,7aS,10aS,10bS,E)-1a-Methyl-8-methylene-5-((4-(2-
(trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)methyl)-2,3,6,7, 
7a,8,10a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]fu-
ran-9(1aH)-one (7c) 
1H NMR (CDCl3, 400 MHz): δ 7.97 (d, J = 7.2 Hz, 1H), 7.77 
(d, J = 8.4 Hz, 1H), 7.72 (s, 1H), 7.65 (t, J = 8 Hz, 1H), 7.50 (t, 
J = 7.6 Hz, 1H), 6.32 (d, J = 3.2 Hz, 1H), 5.79 (t, J = 8.8 Hz, 
1H), 5.69 (d, J = 3.2 Hz, 1H), 5.25 (d, J = 14.4 Hz, 1H), 4.84 
(d, J = 14.4 Hz, 1H), 3.87 (t, J = 9.2 Hz, 1H), 2.89 (d, J = 9.2 
Hz, 1H), 2.82-2.76 (m, 1H), 2.68-2.59 (m, 1H), 2.51-2.18 (m, 
4H), 2.02 -1.99  (m, 1H), 1.72-1.64 (m, 1H), 1.55 (s, 3H), 
1.19-1.13 (m, 1H) ppm. 13C NMR (CDCl3, 100 MHz) δ 169.3, 
144.9, 138.3, 135.1, 132.4, 132.2, 131.7, 128.6, 126.3, 126.2, 
122.7, 122.6, 121.1, 80.9, 63.5, 59.9, 55.0, 42.7, 36.6, 25.3, 
24.1, 23.7, 18.0 ppm. HRMS (ESI) m/z calcd for C24H25F3N3O3 
(M + H)+ 460.4683, found 460.1908. 
5.2.4. (1aR,7aS,10aS,10bS,E)-5-((4-(3-Chlorophenyl)-1H-
1,2,3-triazol-1-yl)methyl)-1a-methyl-8-methylene-2,3,6,7,7a,8, 
10a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-
9(1aH)-one (7d) 
1H NMR (CDCl3, 400 MHz): δ 7.81 (s, 1H), 7. 74 (d, J = 7.6 
Hz, 2H), 7.38-7.30 (m, 2H), 6.33 (d, J = 3.2 Hz, 1H), 5.81 (t, J 
= 8.0 Hz, 1H), 5.70 (d, J = 3.2 Hz, 1H), 5.26 (d, J = 14.8 Hz, 
1H), 4.78 (d, J = 14.4 Hz, 1H), 3.86 (t, J = 9.6 Hz, 1H), 2.89-
2.79 (m, 2H), 2.69-2.62 (m, 1H), 2.49-2.19 (m, 4H), 2.0 (d, J = 
14.4 Hz, 1H), 1.67 (t, J = 12 Hz, 1H), 1.55 (s, 3H), 1.16 (t, J = 
11.6 Hz, 1H) ppm. 13C NMR (CDCl3, 100 MHz) δ 169.31, 
147.1, 138.3, 135.1, 134.9, 132.4, 132.2, 130.3, 128.4, 125.8, 
123.8, 121.1, 119.7, 80.9, 63.4, 59.9, 55.0, 42.7, 36.6, 25.5, 
24.2, 23.6, 18.0 ppm.   HRMS (ESI) m/z calcd for 
C23H25ClN3O3 (M + H)+ 426.1579, found 426.1643. 
5.2.5. (1aR,7aS,10aS,10bS,E)-5-((4-(4-Fluorophenyl)-1H-,2,3-
triazol-1-yl)methyl)-1a-methyl-8-methylene-2,3,6,7,7a,8,10a, 
10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1a 
H)-one (7e). 
1H NMR (CDCl3, 400 MHz): δ 7.82-7.78 (m, 2H), 7.69 (s, 
1H), 7.12 (t, J = 8.8 Hz, 2H), 6.32 (d, J = 2.80 Hz, 1H), 5.80 (t, 
J = 8.4 Hz, 1H), 5.69 (d, J = 3.2 Hz, 1H), 5.25 (d, J = 14.4 Hz, 
1H), 4.77 (d, J = 14.4 Hz, 1H), 3.86 (t, J = 9.6 Hz, 1H), 2.89-
2.79 (m, 2H), 2.69-2.63 (m, 1H), 2.49-2.18 (m, 4H), 2.01 (d, J 
= 15.6 Hz, 1H), 1.70-1.63 (m, 1H), 1.54 (s, 3H), 1.16 (t, J = 
11.6 Hz, 1H) ppm. 13C NMR (CDCl3, 100 MHz) δ 169.2, 
164.1, 161.6, 147.6, 138.3, 135.3, 132.3, 127.6, 127.5, 126.7, 
126.6, 121.1, 118.9, 116.1, 115.9, 80.9, 63.5, 59.9, 55.0, 42.7, 
36.6, 25.2, 24.2, 23.6, 18.0 ppm. HRMS (ESI) m/z calcd for 
C23H25FN3O3 (M + H)+ 410.1874, found 410.1987. 
5.2.6. (1aR,7aS,10aS,10bS,E)-5-((4-(4-Methoxyphenyl)-1H-1,2 
,3-triazol-1-yl)methyl)-1a-methyl-8-methylene-2,3,6,7,7a,8,10 
a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1 
aH)-one (7f) 
1H NMR (CDCl3, 400 MHz): δ 7.76 (d, J = 8.8 Hz, 2H), 7.63 
(s, 1H), 6.97 (d, J = 8.8 Hz, 2H), 6.32 (d, J = 3.2 Hz, 1H), 5.79 
(t, J = 8.0 Hz, 1H), 5.69 (d, J = 2.8 Hz, 1H), 5.24 (d, J = 14.8 
Hz, 1H), 4.75 (d, J = 14 Hz, 1H), 3.88-3.84 (m, 4 H), 2.89-2.79 
(m, 2H), 2.74-2.63 (m, 1H), 2.48-2.18 (m, 4H), 2.01 (d, J = 
15.6 Hz, 1H), 1.65 (t, J = 12.4 Hz, 1H), 1.54 (s, 3H), 1.15 (t, J 
= 14.4 Hz, 1H) ppm. 13C NMR (CDCl3, 100 MHz) δ 169.3, 
159.8, 148.2, 138.3, 135.3, 132.1, 127.1, 123.1, 121.1, 118.4, 
114.4, 80.9, 63.4, 59.9, 55.4, 54.9, 42.7, 36.6, 25.2, 24.1, 23.6, 
18.0 ppm.  HRMS (ESI) m/z calcd for C24H28N3O4 (M + H)+ 
422.2074, found 422.2128. 
5.2.7. (1aR,7aS,10aS,10bS,E)-5-((4-(4-Fluoro-3-methylphenyl) 
-1H-1,2,3-triazol-1-yl)methyl)-1a-methyl-8-methylene-2,3,6,7, 
7a,8,10a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]fur 
an-9(1aH)-one (7g) 
1H NMR (CDCl3, 400 MHz): δ 7.69 (d, J = 8.4 Hz, 1H), 7.58 
(t, J = 5.2 Hz, 1H), 7.05 (t, J = 8.8 Hz, 1H), 6.3 (d, J = 3.2 Hz, 
1H), 5.79 (t, J = 8.4 Hz, 1H), 5.69 (d, J = 2.8 Hz, 1H), 5.25 (d, 
J = 14.4 Hz, 1H), 4.76 (d, J = 14.4 Hz, 1H), 3.86 (t, J = 9.6 Hz, 
1H), 2.89-2.78 (m, 2 H), 2.73-2.69 (m, 1H), 2.48-2.18 (m, 8H), 
2.01 (d, J = 15.2 Hz, 1H), 1.70 (t, J = 15.2 Hz, 1H), 1.54 (s, 
3H), 1.16 (t, J = 12.8 Hz, 1H) ppm. 13C NMR (CDCl3, 100 
MHz) δ 169.3, 162.6, 160.2, 147.7, 138.3, 135.2, 132.2, 129.0, 
128.9, 126.3, 125.6, 125.4, 124.8, 124.7, 121.1, 118.9, 115.7, 
115.4, 80.9, 63.4, 59.9, 54.9, 42.7, 36.6, 25.2, 24.1, 23.7, 18.0, 
14.7 ppm. HRMS (ESI) m/z calcd for C24H27FN3O3 (M + H)+ 
424.2031, found 424.2076.  
5.2.8. (1aR,7aS,10aS,10bS,E)-5-((4-(3,5-bis(Trifluoromethyl) 
phenyl)-1H-1,2,3-triazol-1-yl)methyl)-1a-methyl-8-methylene-
2,3,6,7,7a,8,10a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1, 
2-b]f uran-9(1aH)-one (7h) 
1H NMR (CDCl3, 400 MHz): δ 8.29 (s, 2H), 7.91 (s, 1H), 7.84 
(s, 1H), 6.33 (d, J = 3.6 Hz, 1H), 5.83 (t, J = 8 Hz, 1H), 5.71 
(d, J = 2.8 Hz, 1H), 5.31 (d, J = 14.8 Hz, 1H), 4.82 (d, J = 14.8 
Hz, 1H), 3.87 (t, J = 9.2 Hz, 1H), 2.89-2.81 (m, 2H), 2.69-2.62 
(m, 1H), 2.51-2.20 (m, 4H), 1.99 (d, J = 10.4 Hz, 1H), 1.69 (t, 
J = 11.6 Hz, 1H), 1.55 (s, 3H), 1.17 (t, J = 10 Hz, 1H) ppm. 13C 
NMR (CDCl3, 100 MHz) δ 169.2, 145.7, 138.2, 134.9, 132.7, 
132.6, 132.6, 132.3, 125.7, 124.6, 121.9, 121.8, 121.1, 120.4, 
80.9, 63.4, 59.9, 55.2, 42.7, 36.5, 25.2, 24.2, 23.6, 18.0 ppm. 
HRMS (ESI) m/z calcd for C25H24F6N3O3 (M + H)+ 528.1716, 
found 528.1795. 
5.2.9. 3-(1-(((1aR,7aS,10aS,10bS,E)-1a-Methyl-8-methylene-9-
oxo-1a,2,3,6,7,7a,8,9,10a,10b-decahydrooxireno[2',3':9,10]cy- 
clodeca[1,2-b]furan-5-yl)methyl)-1H-1,2,3-triazol-4-yl)benz- 
oic acid (7i) 
1H NMR (CDCl3, 400 MHz): δ 8.47 (s, 1H), 8.21 (d, J = 7.6 
Hz, 1H), 8.10 (d, J = 8 Hz, 1H), 7.87 (s, 1H), 7.57 (t, J = 7.6 
Hz, 1H), 6.32 (d, J = 2.8 Hz, 1H), 5.82 (t, J = 8.8 Hz, 1H), 5.70 
(d, J = 3.2 Hz, 1H), 5.29 (d, J = 16 Hz, 1H), 4.81 (d, J = 14.4 
Hz, 1H), 3.87 (t, J = 9.2 Hz, 1H), 2.90-2.81 (m, 2H), 2.72-2.17 
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ACCEPTED MANUSCRIPT(m, 5H), 2.03-1.99 (m, 1H), 1.72-1.64 (m, 1H), 1.55 (s, 3H), 
1.20-1.14 (m,1H) ppm. 13C NMR (CDCl3, 100 MHz) δ 170.9, 
169.4, 147.2, 138.3, 135.0, 132.4, 130.9, 130.8, 130.2, 130.0, 
129.3, 127.4, 121.1, 120.1, 81.0, 63.4, 60.0, 55.0, 42.6, 36.5, 
25.2, 24.1, 23.7, 18.0 ppm. HRMS (ESI) m/z calcd for 
C24H26N3O5 (M + H)+ 436.1867, found 436.1958. 
5.2.10. (1aR,7aS,10aS,10bS,E)-5-((4-(3,5-Difluorophenyl)-1H-
1,2,3-triazol-1-yl)methyl)-1a-methyl-8-methylene-2,3,6,7,7a,8, 
10a, 10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-
9(1aH)-one (7j) 
1H NMR (CDCl3, 400 MHz): δ 7.75 (s, 1H), 7.38-7.33 (m, 
2H), 6.78 (t, J = 9.2, 2.4 Hz, 1H), 6.32 (d, J = 3.2 Hz, 1H), 
5.81 (t, J = 8 Hz, 1H), 5.69 (d, 1H), 5.26 (d, J = 14.8 Hz, 1H), 
4.78 (d, J = 14.4 Hz, 1H), 3.87 (t, J = 9.2 Hz, 1H), 2.89 (d, J = 
9.6 Hz, 1H), 2.85-2.79 (m, 1H), 2.71-2.60 (m, 1H), 2.50-2.19 
(m, 4H), 2.0 (d, J = 14.4 Hz, 1H), 1.71-1.64 (m, 1H), 1.55 (s, 
3H), 1.16 (t, J = 10.8 Hz, 1H) ppm. 13C NMR (CDCl3, 100 
MHz) δ 169.3, 164.8, 162.3, 146.4, 138.2, 135.0, 133.6, 132.4, 
121.1, 120.2, 108.7, 103.8, 80.9, 63.3, 60.0, 54.9, 42.6, 36.5, 
25.2, 24.1, 23.7, 18.0 ppm. HRMS (ESI) m/z calcd for 
C23H24F2N3O3 (M + H)+ 428.1780, found 428.1817. 
5.2.11. (1aR,7aS,10aS,10bS,E)-5-((4-(3-Ethynylphenyl)-1H-1, 
2,3-triazol-1-yl)methyl)-1a-methyl-8-methylene-2,3,6,7,7a,8, 
10a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-
9(1aH)-one (7k) 
1H NMR (CDCl3, 400 MHz): δ 7.91 (s, 1H), 7.88 (d, J = 7.20 
Hz, 1H), 7.75 (s, 1H), 7.47 (d, J = 7.6 Hz, 1H), 7.40 (t, J = 7.6 
Hz, 1H), 6.32 (d, J = 3.2 Hz, 1H), 5.80 (t, J = 8 Hz, 1H), 5.70 
(d, J = 2.8 Hz, 1H), 5.26 (d, J = 14.8 Hz, 1H), 4.77 (d, J = 14.4 
Hz, 1H), 3.86 (t, J = 9.6 Hz, 1H), 3.10 (s, 1H), 2.89-2.79 (m, 
2H), 2.66-2.61 (m, 1H), 2.48-2.19 (m, 4H), 2.0 (d, J = 15.6 Hz, 
1H), 1.70-1.63 (m, 1H), 1.54 (s, 3H), 1.21-1.11 (m, 1H) ppm. 
13C NMR (CDCl3, 100 MHz) δ 169.2, 147.5, 138.2, 135.2, 
132.4, 132.0, 130.7, 129.4, 129.1, 126.1, 122.8, 121.1, 119.5, 
83.3, 80.9, 77.8, 63.4, 59.9, 55.0, 42.7, 36.6, 25.2, 24.2, 23.6, 
18.0 ppm. HRMS (ESI) m/z calcd for C25H26N3O3 (M + H)+ 
416.1969, found 416.1931. 
5.2.12. (1aR,7aS,10aS,10bS,E)-1a-Methyl-8-methylene-5-((4-
(pyridin-2-yl)-1H-1,2,3-triazol-1-yl)methyl)-2,3,6,7,7a,8,10a, 
10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1a 
H)-one (7l)                                                                                                
1H NMR (CDCl3, 400 MHz): δ 8.57 (d, J = 3.2 Hz, 1H), 8.19 
(d, J = 8 Hz, 1H), 8.12 (s, 1H), 7.80 (t, J = 8 Hz, 1H), 7.26-
7.23 (m, 1H), 6.32 (d, J = 3.6 Hz, 1H), 5.83 (t, J = 8.4 Hz, 1H), 
5.69 (d, J = 2.8 Hz, 1H), 5.26 (d, J = 14.4 Hz, 1H), 4. 79 (d, J 
= 14.4 Hz, 1H), 3.86 (t, J = 9.6 Hz, 1H), 2.89 (d, J = 9.6 Hz, 
1H),   2.84 -2.78 (m, 1H), 2.68-2.59 (m, 1H), 2.47-2.18 (m, 
4H), 2.01 (d, J = 14.8 Hz, 1H), 1.70-1.63 (m, 1H), 1.54 (s, 3H), 
1.15 (t, J = 12.8 Hz, 1H) ppm. 13C NMR (CDCl3, 100 MHz) δ 
169.2, 150.1, 149.5, 148.9, 138.3, 137.1, 134.8, 132.7, 123.1, 
121.6, 121.0, 120.3, 80.9, 63.3, 59.9, 54.9, 42.6, 36.5, 25.2, 
24.1, 23.5, 18.0 ppm. HRMS (ESI) m/z calcd for C22H25N4O3 
(M + H)+ 393.1921, found 393.1950. 
5.2.13. (1aR,7aS,10aS,10bS,E)-1a-Methyl-8-methylene-5-((4-
(2,4,5-trimethylphenyl)-1H-1,2,3-triazol-1-yl)methyl)-2,3,6,7,7 
a,8,10a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]fur- 
an-9(1aH)-one (7m) 
1H NMR (CDCl3, 400 MHz): δ 7.56 (s, 2H), 7.04 (s, 1H), 6.31 
(s, 1H), 5.79 (t, J = 8.0 Hz, 1H), 5.69 (s, 1H), 5.25 (d, J = 14.4 
Hz, 1H), 4.79 (d, J = 14.4 Hz, 1H), 3.86 (t, J = 9.6 Hz, 1H), 
2.89 (d, J = 9.2 Hz, 1H), 2.83-2.65 (m, 2H), 2.48-2.20 (m, 
13H), 2.04-1.95 (m, 1H), 1.66 (t, J = 15.2 Hz, 1H), 1.55 (s, 
3H), 1.16 (t, J = 13.2 Hz, 1H) ppm. 13C NMR (CDCl3, 100 
MHz) δ 169.3, 147.9, 138.3, 136.9, 135.4, 134.4, 132.6, 132.4, 
132.1, 129.9, 127.0, 121.1, 120.9, 80.9, 63.5, 59.9, 54.9, 42.7, 
36.6, 25.3, 24.2, 23.8, 20.9, 19.5, 19.3, 18.0 ppm. HRMS (ESI) 
m/z calcd for C26H32N3O3 (M + H)+ 434.2438, found 434.2462. 
5.2.14. (1aR,7aS,10aS,10bS,E)-1a-Methyl-8-methylene-5-((4-
(thiophen-3-yl)-1H-1,2,3-triazol-1-yl)methyl)-2,3,6,7,7a,8,10a, 
10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1a 
H)-one (7n) 
1H NMR (CDCl3, 400 MHz): δ 7.69 (d, J = 3.6 Hz, 1H), 7.63 
(s, 1H), 7.45 (d, J = 5.2 Hz, 1H), 7.40-7.38 (m, 1H), 6.31 (d, J 
= 3.6 Hz, 1H), 5.78 (t, J = 8.4 Hz, 1H), 5.69 (d, J = 3.2 Hz, 
1H), 5.24 (d, J = 14.4 Hz, 1H), 4.76 (d, J = 14.8 Hz, 1H), 3.86 
(t, J = 9.2 Hz, 1H), 2.88-2.78 (m, 2H), 2.70-2.61 (m, 1H), 
2.47-2.18 (m, 4H), 2.0-1.95 (m, 1H), 1.70-1.61 (m, 1H), 1.54 
(s, 3H), 1.5 (t, J = 12.8 Hz, 1H) ppm. 13C NMR (CDCl3, 100 
MHz) δ 169.3, 144.5, 138.3, 135.2, 132.1, 131.7, 126.5, 125.8, 
121.3, 121.0, 119.1, 80.9, 63.3, 59.9, 54.8, 42.6, 36.5, 25.2, 
24.1, 23.6, 18.0 ppm. HRMS (ESI) m/z calcd for C21H24N3O3S 
(M + H)+ 398.1533, found 398.1561. 
5.2.15. (1aR,7aS,10aS,10bS,E)-5-((4-(4-Aminophenyl)-1H-1,2, 
3-triazol-1-yl)methyl)-1a-methyl-8-methylene-2,3,6,7,7a,8,10 
a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1 
aH)-one (7o) 
1H NMR (CDCl3, 400 MHz): δ 7.61 (d, J = 9.2 Hz, 2H), 7.56 
(s, 1H), 6.72 (d, J = 8.4 Hz, 2H), 6.29 (d, J = 3.2 Hz, 1H), 5.76 
(t, J = 8.4 Hz, 1H), 5.67 (d, J = 2.8 Hz, 1H), 5.20 (d, J = 14.4 
Hz, 1H), 4.72 (d, J = 14.4 Hz, 1H), 3.83 (t, J = 9.6 Hz, 1H), 
2.87-2.78 (m, 2H), 2.70-2.58 (m, 1H), 2.46-2.16 (m, 4H), 1.98-
1.94 (m, 1H), 1.68-1.58 (m, 1H), 1.52 (s, 3H), 1.13 (t, J = 13.6 
Hz, 1H) ppm. 13C NMR (CDCl3, 100 MHz) δ 169.3, 148.7, 
146.8, 138.3, 135.3, 132.0, 127.0, 121.1, 120.8, 117.9, 115.3, 
80.9, 63.4, 59.9, 54.9, 42.7, 36.6, 25.2, 24.1, 23.6, 18.0 ppm. 
HRMS (ESI) m/z calcd for C23H27N4O3 (M + H)+ 407.2078, 
found 407.2115. 
5.2.16. (1aR,7aS,10aS,10bS,E)-5-((4-(Hydroxymethyl)-1H-1,2, 
3-triazol-1-yl)methyl)-1a-methyl-8-methylene-2,3,6,7,7a,8,10a 
,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1a 
H)-one (7p) 
1H NMR (CDCl3, 400 MHz): δ 7.51 (s, 1H), 6.31 (d, J = 3.2 
Hz, 1H), 5.76 (t, J = 8.4 Hz, 1H), 5.68 (d, J = 3.2 Hz, 1H), 5.20 
(d, J = 14.4 Hz, 1H), 4.82 (d, J = 5.6 Hz, 2H), 4.73 (d, J = 14.8 
Hz, 1H), 3.85 (t, J = 8.8 Hz, 1H), 2.87-2.75 (m, 2H), 2.65-2.56 
(m, 1H), 2.47-2.18 (m, 4H), 2.05 (t, J = 6.4 Hz, 1H), 1.98-1.94 
(m, 1H), 1.69-1.62 (m, 1H), 1.54 (s, 3H), 1.15 (t, J = 10.8 Hz, 
1H) ppm. 13C NMR (CDCl3, 100 MHz) δ 169.2, 148.2, 138.3, 
135.1, 132.5, 121.2, 121.1, 80.9, 63.5, 59.9, 56.9, 54.9, 42.7, 
36.6, 25.3, 24.1, 23.7, 18.0 ppm. HRMS (ESI) m/z calcd for 
C18H24N3O4 (M + H)+ 346.1761, found 346.1776. 
5.2.17. (1aR,7aS,10aS,10bS,E)-1a-Methyl-8-methylene-5-((4-
propyl-1H-1,2,3-triazol-1-yl)methyl)-2,3,6,7,7a,8,10a,10b-oct-
ahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1aH)-one 
(7q). 
1H NMR (CDCl3, 400 MHz): δ 7.23 (s, 1H) 6.30 (d, J = 3.6 
Hz, 1H), 5.73 (t, J = 8.0 Hz, 1H), 5.67 (d, J = 3.2 Hz, 1H), 5.16 
(d, J = 14.4 Hz, 1H), 4.69 (d, J = 14.8 Hz, 1H), 3.84 (t, J = 9.2 
Hz, 1H), 2.87 (d, J = 9.2 Hz, 1H), 2.77-2.58 (m, 4 H), 2.45-
2.17 (m, 4 H), 1.96-1.91 (m, 1H), 1.74-1.58 (m, 3H), 1.54 (s, 
3H), 1.14 (t, J = 11.2 Hz, 1H), 0.96 (t, J = 6.8 Hz, 3H) ppm. 
13C NMR (CDCl3, 100 MHz) δ 169.3, 149.0, 138.3, 135.5, 
131.9, 121.2, 120.2, 80.9, 63.5, 59.9, 54.8, 42.7, 36.7, 27.8, 
25.3, 24.1, 23.8, 22.7, 18.0, 13.9 ppm.  HRMS (ESI) m/z calcd 
for C20H28N3O3 (M + H)+ 358.2125, found 358.2114. 
5.2.18. (1aR,7aS,10aS,10bS,E)-5-((4-Butyl-1H-1,2,3-triazol-1-
yl)methyl)-1a-methyl-8-methylene-2,3,6,7,7a,8,10a,10b-octah- 
ydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1aH)-one (7r) 
1H NMR (CDCl3, 400 MHz): δ 7.22 (s, 1H), 6.30 (d, J = 3.6 
Hz, 1H), 5.73 (t, J = 8.0 Hz, 1H), 5.67 (d, J = 3.2 Hz, 1H), 5.15 
(d, J = 14.4 Hz, 1H), 4.68 (d, J = 14.4 Hz, 1H), 3.84 (t, J = 9.2 
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ACCEPTED MANUSCRIPTHz, 1H), 2.87 (d, J = 9.6 Hz, 1H), 2.77-2.57 (m, 4H), 2.45-2.17 (m, 4H), 1.96-1.91 (m, 1H), 1.68-1.60 (m, 3H), 1.53 (s, 3H), 
1.42-1.33 (m, 2H), 1.14 (t, J = 11.6 Hz, 1H), 0.93 (t, J = 7.6 
Hz, 3H) ppm. 13C NMR (CDCl3, 100 MHz) δ 169.3, 149.2, 
138.3, 135.4, 131.9, 121.1, 120.1, 80.9, 63.4, 59.9, 54.7, 42.7, 
36.6, 31.6, 25.5, 25.3, 24.1, 23.7, 22.4, 18.0, 13.9 ppm. HRMS 
(ESI) m/z calcd for C21H30N3O3 (M + H)+ 372.2282, found 
372.2301. 
5.2.19. (1aR,7aS,10aS,10bS,E)-5-((4-(3-Chloropropyl)-1H-1,2 
,3-triazol-1-yl)methyl)-1a-methyl-8-methylene-2,3,6,7,7a,8, 10 
a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1 
aH)-one (7s) 
1H NMR (CDCl3, 400 MHz): δ 7.30 (s, 1H), 6.30 (d, J = 3.2 
Hz, 1H), 5.74 (t, J = 8.4 Hz, 1H), 5.67 (d, J = 2.8 Hz, 1H), 5.16 
(d, J = 14.4 Hz, 1H), 4.70 (d, J = 14.4 Hz, 1H), 3.85 (t, J = 8.8 
Hz, 1H), 3.57 (t, J = 6.0 Hz, 2H), 2.90-2.84 (m, 3H), 2.76 (t, J 
= 9.2 Hz, 1H), 2.64-2.57 (m, 1H), 2-46-2.13 (m, 6H), 1.94 (d, J 
= 8.8 Hz, 1H), 1.64 (t, J = 11.2 Hz, 1H), 1.53 (s, 3H), 1.14 (t, J 
= 12.4 Hz, 1H) ppm. 13C NMR (CDCl3, 100 MHz) δ 169.3, 
147.1, 138.3, 135.3, 132.1, 121.1, 120.8, 80.9, 63.4, 59.9, 54.8, 
44.3, 42.7, 36.6, 31.8, 25.2, 24.1, 23.7, 22.8, 18.0 ppm. HRMS 
(ESI) m/z calcd for C20H27ClN3O3 (M + H)+ 392.1735, found 
392.1738. 
5.2.20. (1aR,1a'R,4E,4'E,7aS,7a'S,10aS,10bS,10a'S,10b'S)-5,5' 
-((4,4'-(Azanediylbis(methylene))bis(1H-1,2,3-triazole-4,1-diyl 
))bis(methylene))bis(1a-methyl-8-methylene-2,3,6,7,7a,8, 10a, 
10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1a 
H)-one) (9a). 
1H NMR (CDCl3, 400 MHz): δ 7.52 (s, 2H), 6.29 (d, J = 3.2 
Hz, 2H), 5.74 (t, J = 7.6 Hz, 2H), 5.6 (d, J = 2.8 Hz, 2H), 5.15 
(d, J = 14.4 Hz, 2H), 4.74 (d, J = 14.4 Hz, 2H), 3.93 (s, 4H), 
3.84 (t, J = 9.2 Hz, 2H), 2.85 (d, J = 9.2 Hz, 2H), 2.72-2.56 (m, 
4H), 2.47-2.16 (m, 8H), 2.04-1.96 (m, 2H), 1.88-1.74 (m, 2H), 
1.67-1.58 (m, 2H), 1.53 (s, 6H), 1.14 (t, J = 12.4 Hz, 2H) ppm. 
13C NMR (CDCl3, 100 MHz) δ 169.3, 146.5, 138.3, 135.0, 
132.2, 121.9, 121.0, 80.9, 63.3, 60.0, 54.7, 43.8, 42.6, 36.5, 
29.7, 25.2, 24.0, 23.9, 18.0 ppm. HRMS (ESI) m/z calcd for 
C36H46N7O6 (M + H)+ 672.3504, found 672.3538. 
5.2.21. (1aR,1a'R,4E,4'E,7aS,7a'S,10aS,10bS,10a'S,10b'S)-5,5 
'-((4,4'-(Propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))-bis( 
methylene))bis(1a-methyl-8-methylene-2,3,6,7,7a,8,10a, 10b-
octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1aH)-
one) (9b). 
1H NMR (CDCl3, 400 MHz): δ 7.35 (s, 2H), 6.27 (d, J = 3.6 
Hz, 2H), 5.74 (t, J = 8 Hz, 2H), 5.67 (d, J = 2.8 Hz, 2H), 5.14 
(d, J = 14.4 Hz, 2H), 4.76 (d, J = 14.8 Hz, 2H), 3.83 (t, J = 9.2 
Hz, 2H), 2.85 (d, J = 9.2 Hz, 2H), 2.76 (t, J = 7.6 Hz, 4H), 
2.68-2.56 (m, 4H), 2.47-2.16 (m, 8H), 2.06-1.97 (m, 4H), 1.66-
1.60 (m, 2H), 1.53 (s, 6H), 1.13 (t, J = 13.2 Hz, 2H) ppm. 13C 
NMR (CDCl3, 100 MHz) δ 169.3, 148.1, 138.2, 135.2, 132.3, 
121.1, 120.9, 80.9, 63.4, 60.0, 54.9, 42.7, 36.6, 29.3, 25.4, 
24.9, 24.1, 18.0 ppm. HRMS (ESI) m/z calcd for C37H47N6O6 
(M + H)+ 671.3552, found 671.3567. 
5.2.22. (1aR,1a'R,4E,4'E,7aS,7a'S,10aS,10bS,10a'S,10b'S)-5,5 
'-((4,4'-(1,3-Phenylene)bis(1H-1,2,3-triazole-4,1-diyl))bis-(me 
thylene))bis(1a-methyl-8-methylene-2,3,6,7,7a,8,10a,10b-octa- 
hydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1aH)-one) 
(9c) 
1H NMR (CDCl3, 400 MHz): δ 8.30 (s, 1H), 7.86 (s, 2H), 7.82 
(d, J = 3.2 Hz, 2H), 7.49 (t, J = 7.6 Hz, 1H), 6.3 (d, J = 3.2 Hz, 
2H), 5.81 (t, J = 8.4 Hz, 2H), 5.68 (d, J = 3.2 Hz, 2H), 5.26 (d, 
J = 14.8 Hz, 2H), 4.81 (d, J = 14.4 Hz, 2H), 3.86 (t, J = 9.2 Hz, 
2H), 2.88 (d, J = 9.6 Hz, 2H), 2.84-2.78 (m, 2H), 2.64-2.60 (m, 
2H), 2.49-2.19 (m, 10H), 1.70-1.62 (m, 2H), 1.54 (s, 6H), 
1.20-1.12 (m, 2H) ppm. 13C NMR (CDCl3, 100 MHz) δ 169.3, 
148.0, 138.3, 135.1, 132.5, 131.1, 129.6, 125.5, 122.9, 121.1, 
119.7, 80.9, 63.4, 59.9, 55.0, 42.7, 36.6, 25.2, 24.2, 23.7, 18.0 
ppm. HRMS (ESI) m/z calcd for C40H45N6O6 (M + H)+ 
705.3395, found 705.3472. 
5.2.23. (1aR,7aS,8R,10aS,10bS,E)-5-((4-(3,5-bis(Trifluoromet- 
hyl)phenyl)-1H-1,2,3-triazol-1-yl)methyl)-8-((dimethylamino) 
methyl)-1a-methyl-2,3,6,7,7a,8,10a,10b-octahydro-oxireno[2 
',3': 9,10]cyclodeca[1,2-b]furan-9(1aH)-one (10) 
1H NMR (CDCl3, 400 MHz): δ 8.28 (s, 2H), 7.88 (s, 1H), 7.83 
(s, 1H), 5.75 (t, J = 8 Hz, 1H), 5.68 (d, J = 14.4 Hz, 1H), 4.82 
(d, J = 14.4 Hz, 1H), 3.89 (t, J = 9.6 Hz, 1H), 2.90-2.71 (m, 
3H), 2.66-2.56 (m, 1H), 2.50-2.17 (m, 12H), 1.87-1.82 (m, 
1H), 1.58-1.55 (m, 4H), 1.14 (t, J = 13.2 Hz, 1H) ppm. 13C 
NMR (CDCl3, 100 MHz) δ 176.8, 145.4, 136.0, 132.8, 132.6, 
132.2, 131.6, 125.6, 121.9, 121.7, 120.4, 81.2, 64.3, 59.7, 57.5, 
54.9, 45.9, 44.3, 41.8, 36.9, 26.4, 24.2, 24.0, 18.0 ppm. HRMS 
(ESI) m/z calcd for C27H31F6N4O3 (M + H)+ 573.2295, found 
573.2307. 
 
5.3. Methodology for the in vitro 60 human cancer cell 
screening assay 
Anti-cancer activity screening against the panel of 60 human 
cancer cell lines was carried out at the National Cancer 
Institute utilizing a reported literature procedure [75]. Briefly, 
RPMI 1640 medium with 5% fetal bovine serum and 2 mM L-
glutamine was used for growing the NCI-60 human tumor 
cells. Initially the tumor cells were inoculated into 96-well 
microtiter plates in 100 µL of medium at plating densities 
starting from 5,000 to 40,000 cells per well. The range of cell 
numbers is dependent on the doubling time of the individual 
tumor cell lines. The plates were then incubated at 37 °C for 24 
hours prior to addition of the submitted compounds. After 24 
h, two microtiter plates of each tumor cell line were fixed in 
situ with TCA. The optical density reading at this point 
represents the cell population for each tumor cell line at the 
time of compound addition (ODtzero). The MMB dimers were 
dissolved in DMSO at 400-fold concentration to the desired 
final maximum test concentration, and stored at -80 °C. Then, 
an aliquot part of the frozen concentrate was thawed and 
diluted to 10-4 M concentration with medium containing 50 
µg/mL gentamicin. A control sample with just DMSO was also 
prepared. Aliquot parts (100 µL) of the different MMB triazole 
dilution controls were added to the appropriate microtiter wells 
containing 100 µL of medium, resulting in the required final 
drug concentrations of 10-5 M and 0 M (control). Once the 
MMB triazoles were added, the microtiter plates were 
incubated for 48 hrs at 37 °C and 100 % relative humidity. 
Cold TCA was used to terminate the assay for adherent cells. 
Cells were fixed by the addition of 50 µL of cold 50 % (w/v) 
TCA and further incubated for 1 hr at 4 °C. The supernatant 
was discarded, and the microtiter plates were splashed five 
times with water and air dried. Sulforhodamine B (SRB) 
solution (100 µL) at 0.4 % (w/v) in 1 % acetic acid was added 
to each well, and plates were incubated for another 10 minutes 
at room temperature. After SRB staining, free SRB was 
removed by washing five times with 1 % acetic acid. Bound 
SRB stain was successively dissolved with 10 mM trizma base, 
and the optical density was measured at a wavelength of 515 
nm. 
The growth inhibitory or cytotoxicity effects of the MMB 
triazoles in the above cellular assay was measured by 
determining percentage cell growth (PG) inhibition. Optical 
density (OD) measurements of SRB-derived color just before 
exposing the cells to the test compound (ODtzero) and after 
48hrs exposure to the test compound (ODtest) or the control 
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accessed from the National Cancer Institute database: 
http://dtp.nci.nih.gov/branches/btb/ivclsp.html 
5.4. M9 ENL1 cell and primary AML cell assays  
MMB triazole analogs were screened for cytotoxicity against 
the M9 ENL1 cell line and against primary AML specimens as 
follows: M9 ENL1 cells were plated at a density of 106 
cells/mL in alpha-MEM culture media (Invitrogen) 
supplemented with 5% human plasma, 20% FBS, and the 
cytokines SCF, IL-3, IL-7, and FLT3 (Peprotech). For primary 
AML specimens, cells were obtained from volunteer donors. 
Informed consent was obtained in accordance with the 
Declaration of Helsinki. Cells were isolated from the samples 
using Ficoll-Paque (GE Healthcare Bio-Sciences, Pittsburgh, 
PA) density gradient separation. In some cases, cells were 
cryopreserved in freezing medium of Iscove modified 
Dulbecco medium (IMDM), 40% fetal bovine serum (FBS), 
and 10% dimethylsulfoxide (DMSO) or in CryoStor CS-10 
(VWR, West Chester, PA). Cells were cultured in serum-free 
medium (SFM), prepared with Iscove’s MDM supplemented 
with 20% BIT 9500 serum substitute (StemCell Technologies), 
LDL, and beta-mercaptoethanol, for 1 hour before the addition 
of the MMB triazole derivatives.  Drugs were diluted from a 
DMSO stock into PBS such that the final concentration of 
DMSO did not exceed 0.5%.  Flow cytometric analysis was 
performed by co-staining with Annexin V and 7-AAD, 
according to manufacturer specifications, to identify the 
percentage of non-apoptotic cells which was defined as the 
population with negative staining for both labels. The 
percentage of non-apoptotic cells observed was normalized to 
that of the vehicle control and dose-response curves were 
analyzed using GraphPad Prism software to determine EC50 
values.  All analyses were conducted in triplicate. 
5.6. Inhibition of p65 phosphorylation by 7h in primary cells 
from AML patients  
Primary AML cells were exposed to variable concentrations of 
PTL (1.25, 2.5, 5.0, and 10 µM) or 7h (0.30, 0.62. 1.25, and 
2.5 µM) for 6h. Cell lysates were obtained and diluted in 5× 
SDS–PAGE sample buffer (10% w/v SDS, 10 mM DDT, 20% 
glycerol, 0.2 M Tris–HCl, pH 6.8, 0.05% w/v bromophenol 
blue), and run on 8–10% SDS–PAGE gels. Protein gels were 
then transferred to PVDF membrane and blocked with 5% 
milk in 0.1% TBST (20 mM Tris–HCl pH 7.5, 137 mM NaCl, 
0.1% Tween 20), followed by incubation with antibodies 
against p-p65(ser-536) (Cell Signaling). 
5.7. Effect of PTL, 7h and 10 on glutathione levels in primary 
cells from AML patients 
Bulk primary human AML cells were cultured and/or treated at 
1 million/mL in Iscove’s modified Dulbecco’s medium-based 
serum-free media. For drug treatment, cells were preincubated 
in the media for 1 h before the addition of drugs, and the 
treatment time was 24 h. Glutathione quantification is based on 
the principle that reduced glutathione (GSH) and 5,5-
dithiobis(2-nitrobenzoic) acid can react and produce free TNB 
molecules that emit at 412 nm. Therefore, the amount of GSH 
is directly proportional to the rate of TNB production over 
time. Briefly, glutathione samples were prepared by lysing 
primary AML cells in freshly made glutathione assay lysis 
buffer (16 mM KH2PO4, 82 mM K2HPO4, 5 mM EDTA, 0.1% 
Triton X-100, 6 mg/mL of sulfosalicylic acid). Supernatants 
were collected and used for three measurements: 1) amount of 
total glutathione (GSH + GSSG) by measuring the rate of TNB 
production over time; 2) amount of oxidized glutathione 
(GSSG) by first derivatizing GSH with 2-vinylpyridine 
(Sigma) and then measuring the rate of TNB production over 
time; 3) quantification of total protein with Bradford assay 
(Bio-Rad). After completing these three measurements, the 
GSH level is determined using following formula: 
[GSH] = [Total glutathione]-2x[GSSG].  
The glutathione level is expressed as nM/mg of total protein. 
5.8. Inhibition of HSR-GBM1 stem-like glioblastoma cells by 
Compound 7h. 
The HSR-GBM1 (020913) neurosphere cell line was a kind 
gift from Dr. Angelo Vescovi. Cells were passaged as 
previously described (Galli et al27). For growth assays, 8,000 
cells were plated in each well of a 96-multiwell plate. 
Following recovery for 24 hours, drug or vehicle (DMSO) 
were added such that final DMSO concentration was 0.1%. 
Cell counts were performed 48 hours following the addition of 
drug using the Guava 5HT flow cytometer and Guava 
Viacount reagent (Millipore, Billerica, MA). The calculated 
EC50 value for 7h was 1.11 µM. One-way ANOVA was 
performed. **** = p<0.001; ns = not significant. 
 
5.9. Inhibition of NF-κB and breast cancer cell proliferation by 
compound 7h 
5.9.1. Cell proliferation assays 
500-1000 TMD-231 cells were plated in 96-well plates and 
drug treatment was initiated a day after plating. Each treatment 
condition contained six wells. After three days of treatment, 
bromodeoxyuridine incorporation-ELISA was performed as 
per manufacturer’s instructions (Millipore; cat # QIA58-
1000TEST). Results presented are from two biological 
replicates, each condition with six technical replicates. 
5.9.2. Electrophoretic mobility shift assay (EMSA)  
EMSAs with whole cell lysates using 32P-radiolabelled probes 
with NF-κB and Oct-1 (as a control) binding sites was 
performed as described previously [50]. Oligonucleotides with 
NF-κB and Oct-1 binding sites were purchased from Promega 
(NF-κB, Cat# E329A; Oct-1, Cat# E324B). For supershift 
assays, DNA-protein complexes were incubated with antibody 
against p65 (Cell Signaling, cat# 3034) and p50 (Millipore, cat 
# 06-886) subunits for 10 minutes on ice prior to loading. 
5.9.3. Western blotting 
Cell lysates were prepared using RIPA buffer and were 
subjected to Western blotting as described previously [76] and 
probed with IκBα antibody (Cell Signaling, Cat#: 9242S) and 
reprobed with antibody against β-actin (Sigma, Cat#: A5441) 
as a loading control. TNFα was purchased from Peprotech 
(Cat# 315-01A). 
5.10. Molecular modeling 
The amino acid sequence of IKKβ was retrieved from the 
Uniprot database (http://www.uniprot.org/).  For full length 
three-dimensional structure prediction, the amino acid 
sequence of IKKβ was submitted to the I-TASSER server 
(http://zhanglab.ccmb.med.umich.edu/I-TASSER/). I-TASSER 
predicts protein structure utilizing the fold recognition and ab 
initio approach.  The structure from I-TASSER was then 
energy-minimized in a cubic box containing water (SPC) and 
solvent (NaCl) for 5,000 steps using GROMACS simulation 
package.  Energy minimized structures were then used for 
docking studies. 
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Protein ligand docking was performed using Autodock-VINA 
running on a 32 core Linux server with Raccoon2 interface 
(Windows 7); the grid box was kept large enough to cover the 
entire protein in order to ensure unbiased docking searches. 
Although computationally intensive, this method allows 
compounds to freely choose their binding region. Ligands were 
converted to autodock format (.pdbqt) using OpenBabel before 
the docking search.  Results from Autodock-VINA were then 
analyzed in Pymol, and interacting residues were identified 
using LigPlot+ [67, 77].  
5.10.2. Molecular Dynamics Simulation   
MD simulations were performed using the Desmond 
Molecular Dynamics system, version 2016.4, D.E. Shaw 
Research, New York, NY.  The IKKβ molecule alone or 
complexed with 7h or 10 was first immersed in an 
orthorhombic solvent box containing SPC water, counter-ions 
and 0.15 M NaCl.  MD simulation for 50ns was performed 
with default settings. 
5.10.3 IKKβ in silico mutagenesis/docking 
For mutating amino acid residues including SER181 and 
CYS179, we used the pymol mutagenesis plugin.  Mutated 
structures were then simulated for 25ns using the protocol 
mentioned above.  Simulated structures were then used in 
docking studies.  For protein-ligand docking we used the same 
protocol mentioned previously, except in this case we focused 
only on the KD domain for interactions, since we knew that 7h 
targets only the KD domain.  
5.10.4 Covalent docking 
Covalent docking was performed utilizing the covalent 
docking module (Glide) from the Schrodinger small molecule 
drug discovery suite.  Ligands were first prepared using the 
Ligprep module and then used as an input for the covalent 
docking studies.  For compounds 7h and PTL, the reaction 
type was set to Michael addition to a double bond and for 
compounds DMAPT and 10 the reaction type was set to 
nucleophilic addition.  Docking was performed using a Pose 
prediction (thorough) procedure with the minimization radius 
set to default.  Scoring was performed using the MM-GBSA 
method.  The top 10 poses were then ranked based on cDock 
affinity scores.   
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• Design and synthesis of triazole derivatives of melampomagnolide B (MMB). 
• Screening of MMB triazoles against hematological and solid tumor cell lines. 
• MMB triazole inhibition of p65 and IκBα phosphorylation, and NF-κB binding to DNA 
• Structural modeling of interaction of MMB triazoles with the IKKβ protein subunit.  
